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“You can’t connect the dots looking forward, you can only connect them looking backwards. 
So you have to trust that the dots will somehow connect in your future. You have to trust in 
something - your gut, destiny, life, karma, whatever. Because believing that the dots will 
connect down the road, will you give the confidence to follow your heart even when it leads 
you off the well-worn path - and that will make all the difference.” 
- Steve Jobs 
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ABSTRACT 
 Myelodysplastic Syndromes (MDS) with deletion of chromosome 5q (del(5q) are malignant 
bone marrow disorders characterized by macrocytic anemia, chronic transfusion dependency and an 
increased risk of progression to acute myeloid leukemia. A high proportion of patients with lower-risk 
del(5q) myelodysplastic syndromes will respond to lenalidomide treatment, but more than 40% of 
patients have progressed to acute leukemia five years after starting treatment. In this thesis, we 
characterized the rare MDS stem cells and bone marrow microenvironment of low-risk del(5q) MDS 
and studied whether certain somatic mutations are associated with disease progression.  
 We isolated stem and progenitor cells from lower-risk MDS patients by flow cytometric cell 
sorting and characterized these populations functionally and molecularly. By fluorescence in situ 
hybridisation we found the distinct stem and progenitor cells to be clonally involved. This allowed us 
to determine that the hierarchical organization in del(5q) MDS is similar to that of healthy bone 
marrow. Exploiting the fact that the vast majority of MDS cases harbour somatic mutations we 
employed a fate-mapping approach and observed that all somatic mutations found in the bulk bone 
marrow could be traced back to MDS stem cells. We observed that the del(5q) abnormality preceded 
the acquisition of additional mutations. Hypothesizing that the acquisition of certain somatic 
mutations might help explain progression in del(5q) MDS, we used a cohort of 35 longitudinally 
sampled patients to study whether certain mutations are associated with disease progression. Overall, 
the mutational landscape in a pure del(5q) cohort differed from low-risk MDS in general. Thirteen 
patients progressed to high-risk MDS or leukemia at a median of 85 months after diagnosis. We found 
progression to be associated with the detection of a limited subset of new mutations, i.e., TP53, TET2, 
and RUNX1. Of nine patients who progressed to AML, all were treated with lenalidomide and 7 were 
found to have mutations in TP53, which were present in the earliest sample in one case and acquired 
in the remaining six cases. Importantly, the new mutations were detected well before signs of clinical 
progression occurred.  
 Whether or not the microenvironment is perturbed or merely a bystander has been a heavily 
contentious issue in the literature - not only for MDS but for myeloid diseases in general. Comparing 
gene expression in cultured mesenchymal stromal cells from del(5q) and normal patients 
demonstrated no significant differences. Bone marrow biopsies in del(5q) MDS patients before and 
during lenalidomide treatment revealed significantly higher microvessel density (MVD) in del(5q) 
MDS compared to normal controls. In all patients analyzed, MVD decreased upon lenalidomide 
treatment, increasing again upon therapeutic failure. Analysis of staining patterns did not reveal 
quantitative differences in the expression of previously associated MSC markers between del(5q) 
MDS and normal bone marrow, suggesting that lenalidomide's main therapeutic effect is independent 
of reshaping the cellular composition of the microenvironment. Furthermore, as abnormal 
megakaryocytes with hypolobated nuclei constitute one of the hallmarks of del(5q) MDS and as 
megakaryocytes have recently been implicated as important niche cells in the regulation of HSC, we 
studied megakaryocytes as a component of the non-mesenchymal niche in MDS. We provide 
evidence that the pathognomonic hypolobation is directly associated with the clonal del(5q) 
aberration. Despite lenalidomide leading to complete clinical and cytogenetic responses, the 
pathognomonic megakaryocytes with hypolobated nuclei persisted in all patients. Our observation of 
high clonal involvement in MEP suggests that the entire megakaryocytic lineage from HSC to MEP to 
megakaryocytes might be resistant to treatment with lenalidomide. 
 In aggregate, our findings indicate no major perturbations in the mesenchymal niche. Instead, 
we find hematopoietic niche cells in the form of megakaryocytes to be treatment-resistant. As HSC 
continue to acquire somatic mutations, the risk of progression is associated with a limited set of 
mutations, warranting regular mutational profiling in patients treated with lenalidomide. 
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1 NORMAL HEMATOPOIESIS AND STEM CELLS 
Healthy individuals depend on the adequate production of vast numbers of differentiated 
blood cells every day. In a carefully orchestrated process known as hematopoiesis, mature 
blood cells are produced from undifferentiated stem and progenitor cells via a complex series 
of steps that are still incompletely understood. With notable exception mainly in the 
lymphoid compartment, the lifespan of most hematopoietic cells is extremely short – from 
hours to days. This short life span necessitates the continuous production of vast numbers of 
cells to replace these lost cells. During each hour of each day over the lifetime of the 
individual 15 x 109 erythrocytes and 15 x 109 white blood cells are produced (Williams, 
2000). When early anatomists examined the bone marrow they noted that the various 
hematopoietic lineages and differentiation stages exhibited a wide spectrum of different cell 
morphologies. More than 100 years ago, Alexander Maximov was the first to propose the 
existence of blood stem cells sitting at the apex of the hierarchical production of all blood 
cells (Maximov, 1909). 
 
1.1 HEMATOPOIETIC STEM CELLS 
The key to sustained hematopoiesis is the hematopoietic stem cell. Studies aimed at 
elucidating these enigmatic cells were prompted by the clinical need for cells capable of 
protecting humans exposed to minimum lethal doses of irradiation or chemotherapy 
(summarized in (Thomas, 1991)). Thus, the original path to the identification of 
hematopoietic stem cells started in the wake of the bombings of Hiroshima and Nagasaki at 
the end of the second World War. Those individuals who died from exposure to lower 
radiation doses either bled to death due to low platelet counts or had severely compromised 
immune function and succumbed to otherwise nonpathogenic infections. The first 
explanation for the aforementioned observations came from experiments with mice that were 
given varying doses of whole body-irradiation. At the minimal lethal dose, the mice died 
approximately two weeks after radiation exposure from hematopoietic failure. Interestingly, 
however, using lead to shield the spleen or a single bone saved the mice from otherwise lethal 
doses of radiation (Jacobsen et al., 1949). Infusion of syngeneic marrow after irradiation 
similarly rescued these irradiated mice from otherwise fatal failure of the hematopoietic 
system (Lorenz et al., 1951). That this protective effect was cell-mediated (via direct 
repopulation of the hematopoietic system) rather than due to released humoral factors that 
caused the recipientsʼ cells to repair the irradiation damage was shown later by three 
independent groups in 1956 (Ford et al., 1956; Makinodan, 1956). 
Despite that these repopulation experiments demonstrated the functional importance of stem 
cells, it were the seminal experiments performed by Till, McCulloch, Wu, Becker, and 
Siminovitch, who discovered that mice at their time of death, i.e., two weeks after irradiation, 
had developed colonies of myeloid, erythroid and megakaryocytic cells in their spleens. 
Interestingly, the number of formed spleen colonies correlated directly with the number of 
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bone marrow cells originally injected, with approximately 1 colony being generated per 7,000 
bone marrow cells injected.  Accordingly, the cells that gave rise to these colonies were 
dubbed colony-forming units-spleen (CFU-S) (Till and McCulloch, 1961). Using low doses 
of irradiation Becker et al. pre-irradiated bones and thereby induced unique chromosomal 
breaks in most hematopoietic cells, allowing to test whether these colonies of blood cells are 
clonal, i.e., derived from single precursor cells (Becker et al., 1963). The surviving cells 
exhibited chromosomal breaks that were radiation-induced and repaired, thus marking each 
clonogenic hematopoietic cell. Of note, all dividing cells within a single spleen colony, which 
contained different types of blood cells, contained the same unique chromosomal marker. In 
addition, each colony displayed its own unique chromosomal marker. Furthermore, when 
single spleen colonies were re-injected into a second set of lethally-irradiated mice, donor-
derived spleen colonies contained the same unique chromosomal marker, indicating that these 
colonies had been regenerated from the same single cell that had generated the initial colony 
(Siminovitch et al., 1963). In rare cases, these colonies contained sufficient numbers of 
regenerative cells that were able to both prevent death from radiation-induced loss of blood 
cells in secondary recipients (radioprotection), and to spawn myeloerythroid and lymphoid 
cells exhibiting markers of the donor-injected cells (Wu et al., 1968).  
Siminovitch et al. proposed the existence of a population of radioprotective cells within the 
bone marrow, termed hematopoietic stem cells, that are capable of both self-renewal as well 
as multi-lineage differentiation (Siminovitch et al., 1963). This remains the enduring 
definition of stem cells (Weissman, 2000). 
In the decades that followed, substantial efforts were aimed at the purification and 
characterization of these cells. In the beginning, enrichment of the progenitor fraction was 
done by physical means (Visser and De Vries, 1990). However, with the invention of flow 
cytometric cell sorting by the Herzenberg group at Stanford, an ever-increasing panel of cell 
surface markers could be used to purify rare populations (Hardy et al., 1982; 1983; Hulett et 
al., 1969). The accompanying development of clonal assays of all major hematolymphoid 
precursors in mice (Ezine et al., 1987; Whitlock et al., 1987), facilitated the study of the 
isolated candidate progenitors' characteristics. In the mouse, this approach ultimately led to 
the isolation of clonogenic multipotent progenitors with a distinctive marker profile that 
proved to be hematopoietic stem cells (Spangrude et al., 1988; Uchida and Weissman, 1992). 
Using in vivo limiting dilution analysis, two classes of multipotent cells - long-term (LT-
HSCs) and short-term hematopoietic stem cells (ST-HSCs) - could be separated from one 
another suggesting heterogeneity within the most primitive compartment (Morrison and 
Weissman, 1994). While the long-term subset continuously self-renews for the life of the 
host, the short-term subset retains self-renewal capacity for approximately 8 weeks and then 
gives rise to multipotent progenitors (MPPs) (Morrison et al., 1997). Based on a difference in 
surface markers, these three different stem cell subsets can be prospectively isolated. The 
resultant downstream progeny are two kinds of oligolineage-restricted cells: common 
lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs). While CLPs at the 
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clonal level are restricted to give rise to B lymphocytes, T lymphocytes, and natural killer 
(NK) cells (Kondo et al., 1997), the common myeloid progenitors give rise to 
myelomonocytic (GMP) and megakaryocytic/erythroid progenitors (MEPs) (Akashi et al., 
2000).  
 
1.1.1 Human HSC 
Attempts at isolating human Hematopoietic Stem and Progenitor cells were initially 
hampered by the fact that the cell surface markers differ significantly between mouse and 
man. Thus, inherent characteristics of stem cells, conserved across different species, such as 
the low uptake of certain fluorescent dyes like Rhodamine 123 and Hoechst 33342, were 
exploited for the isolation of these cells by FACS (Bertoncello et al., 1985; 1988; Chaudhary 
and Roninson, 1991; Pallavicini et al., 1985; Spangrude and Johnson, 1990). 
CD34 was the first cell surface marker shown to enrich for primitive human progenitors 
(Civin et al., 1984). Within normal bone marrow, this marker is present on 1-2% of cells. 
After prospective isolation of cells bearing this marker, Civin et al. demonstrated that almost 
all progenitor cell activity, as assessed by in vitro colony-forming-unit (CFU) assays, was 
confined to CD34+ cells. Due to the lack of sensitive functional assays, long-term 
repopulation could not be assessed. However, by co-culturing with either human or murine 
stromal cells, candidate populations of candidate human stem cells could be interrogated for 
their ability to sustain hematopoietic colony growth after more mature progenitor cells had 
formed colonies (Simmons et al., 1987; Sutherland et al., 1989; Testa and Dexter, 1991). 
After an initial co-culture with stromal cells for 5-12 weeks, cells are plated in 
methylcellulose and assessed for their ability to form erythroid and myeloid colonies. The 
cells were termed Long-Term-Culture-Initiating Cells (LTC-ICs). However, the 
shortcomings of these assays were that they only assessed the myeloid potential of the 
candidate stem cells and not multi-lineage potential. Moreover, these assays fail to detect the 
capacity for self-renewal (Spooncer et al., 1985). With the advent of humanized mouse 
models, xenotransplantation assays became feasible (Kamel-Reid and Dick, 1988; McCune et 
al., 1988; Mosier et al., 1988). In these assays, human target cells are transplanted into 
immunocompromised mice. Successive improvements yielded a model, where Non-Obese 
Diabetic (NOD) were crossed with Severe Combined Immune Deficient (SCID) mice 
became the preferred host (Shultz et al., 1995). However, the high incidence of thymic 
lymphomas and the fact that murine NK cells persisted in these mice hampered the length 
with which these experiments could continue. Generating mice with the additional absence of 
the Interleukin-2-gamma chain (Shultz et al., 2005), led to a complete absence of murine B, T 
and NK cells. These mice, dubbed NSG mice (NOD/SCID/gamma), did not develop 
lymphomas and enabled long-term experiments with a 5-fold improvement in human 
engraftment. 
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In addition to murine xenotransplantation assays, functional evidence for human stem cells 
comes from patients that are being transplanted with autologous bone marrow or G-CSF-
mobilized peripheral blood for several hematologic malignancies. Usually, unseparated 
hematopoietic cells from bone marrow - or nowadays collected from G-CSF-mobilized 
peripheral blood - are harvested, stored frozen and re-infused after conditioning the host bone 
marrow with radiation and/or chemotherapy and immunosuppressive treatment enabling the 
engraftment of the given cells. However, evidence for the ability of certain cell surface 
markers to enrich for stem cells comes from breast-cancer patients receiving mobilized 
peripheral blood cells selected for expression of CD34 and CD90 and resulting in long-term 
multilineage engraftment (Negrin et al., 2000). Similar studies in patients with lymphoma and 
myeloma confirmed that the long-term repopulating activity is confined to this population of 
cells (Michallet et al., 2000; Vose et al., 2001). However, as the transplanted cells are not 
permanently marked (e.g. genetically), these experiments do not exclude the possibility of 
endogenous reconstitution, and are therefore not an unequivocal proof of stem cell activity. 
With progression of the field, the phenotype of human HSC has become increasingly refined. 
The subset of human bone marrow cells defined by CD34+CD38-CD90+ enriches for 
multipotent human stem cells (Baum et al., 1992). Majeti et al. demonstrated the existence of 
human multipotent progenitors capable of giving rise to lymphoid- as well as myeloid cells 
but lacking the ability to self-renew (Majeti et al., 2007). Using the immunophenotype of 
lineage-CD34+CD38-CD90+CD45RA- they were able to separate HSC from non-self-
renewing MPP, defined by lineage-CD34+CD38-CD90-CD45RA+. Further characterization 
of these cells by a different group demonstrated that single cells could generate lymphoid 
colonies as well as myelomonocytic cells (Doulatov et al., 2010). Using a slight variation in 
markers, a similar population was identified as the murine equivalent to LMPP (Goardon et 
al., 2011). 
The more mature downstream myeloid progenitors are found within the lineage-
CD34+CD38+ subset. By prospectively isolating cells based on the expression of CD123 and 
CD45RA and using colony forming assays in methylcellulose, cell populations could be 
purified analogous to what was known from murine studies (Manz et al., 2002). Analysis of 
gene expression demonstrated the expression of lineage-restricted genes in these subsets. 
Furthermore, these populations neither have any significant LTC-IC activity nor do they 
possess the ability to differentiate to lymphoid cells in vitro. 
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Our current understanding of the hematopoietic hierarchy, with its various stem and 
progenitor cell compartments giving rise to all mature blood cell elements is depicted in 
Figure 1.  
 
Figure 1. The Hematopoietic Hierarchy. The stem cell compartment is somewhat heterogenous and 
consists of different subpopulations that all can give rise to both all the various myeloid and lymphoid 
cells, but differ in their ability to self-renew. Hematopoietic stem cells (HSC) can self- renew for the 
entire lifetime of the organism, the Multipotent progenitor population / lympho-myeloid progenitors 
(LMPP) can still give rise to all mature blood cells but lack any self-renewal capacity. Among the 
progenitor cells, the common lymphoid progenitor (CLP) gives rise to cells of the B- cell, T-cell and 
NK-cell lineage, while the common myeloid progenitors (CMP) give rise to all myeloid cells. They 
themselves give rise to bipotent progenitors, i.e., the megakaryo-erythroid- progenitor (MEP) and 
granulocyte-monocyte-progenitor (GMP), which produce mature offspring, eg erythrocytes, 
thrombocytes, monocytes, and granulocytes. CD markers shown depict the immunophenotype used 
for isolating these subpopulations. Drawn from scratch with Keynote.  
 
 
1.2 CANCER STEM CELLS 
While normal hematopoiesis has clearly been shown to be hierarchically organized, it is still a 
matter of debate whether this feature remains true for malignant hematopoiesis. This debate 
extends to malignancies in general and is based on two principle models (Clevers, 2011; 
Magee et al., 2012; Reya et al., 2001; Visvader and Lindeman, 2008). In the stochastic 
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model, all cells within a tumor are thought to have equal potential for tumor propagation. The 
alternative (termed hierarchical) model posits that only a small and distinct subpopulation of 
cells possess the ability to spawn the malignancy. Central to this model is the existence of 
stem cells, having the unique potential for self-renewal as well as the ability to produce all 
other cells in the clonal malignant offspring. The existence of rare and distinct cancer stem 
cells has been demonstrated in leukemia (Bonnet and Dick, 1997; Lapidot et al., 1994) as 
well as solid organ malignancies (Ailles and Weissman, 2007; Al-Hajj et al., 2003; Dalerba et 
al., 2007; Singh et al., 2004). However, melanoma xeno-transplantation studies are 
experimental evidence for the stochastic model as 25% of all cells, without any selection, 
were able to reconstitute the tumor in mice (Quintana et al., 2008). Thus, it is likely that both 
models exist and that tumor development patterns differ between various malignancies. 
Based on the seminal work by John Dick and colleagues, who demonstrated that only 
CD34+CD38- cells from AML patients were able to propagate the disease, it was assumed 
that cancer stem cells in Acute Myeloid Leukemia (AML) might arise from normal HSC 
(Bonnet and Dick, 1997; Lapidot et al., 1994). This concept was however challenged by a 
study demonstrating that CD38-antibodies impacted the engraftment of CD38+ cells (Taussig 
et al., 2008). In addition, subsequent studies demonstrated that CD34+CD38+ cells possess 
significant leukemia-initiating capacity. Jamieson and co-workers proposed transformed 
GMP as the candidate leukemic stem cells in blast-crisis CML (Jamieson et al., 2004). 
Similarly, a subgroup of AML-patients was found to have leukemia initiating cells with a 
GMP-like immunophenotype of CD34+CD38+CD45RA+ (Goardon et al., 2011). In 
addition, recent studies from our group in MDS patients with monosomy 7, demonstrated a 
significantly expanded GMP-population suggesting that perturbations in the stem and 
progenitor compartments of high-risk MDS are more similar to AML than low-risk MDS 
(Dimitriou et al., 2016). Hence, the term "cancer stem cell" does not necessarily imply that a 
normal stem cell has been transformed to be the cell of origin. The only prerequisite is the 
ability to self-renew. Normal stem cells already have this ability while downstream 
committed progenitors or mature cells need to acquire this feature aberrantly.  
Despite their usefulness, one of the shortcomings of xenotransplantation models is related to 
taking the cells of interest out of their natural habitat. Despite the fact that AML is quite an 
aggressive malignancy, only about half of all samples engraft in immunocompromised mice. 
It has become clear that other supporting cells and the stromal microenvironment can play 
important roles in sustaining the leukemia. Moreover, growth factors and adhesion molecules 
may species-specific and not permit engraftment of human cells in mice. Applying genetic 
lineage tracing to murine models of cancerogenesis clearly identified examples of cancer 
stem cells (Chen et al., 2012; Schepers et al., 2012). Definitive evidence for human cancer 
stem cells would require proof of their existence in the patients themselves. 
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2 THE MYELODYSPLASTIC SYNDROMES 
2.1 HISTORY 
The concept of anemia anteceding acute leukemia was recognized by von Leube at the 
beginning of the 20th century (Leube, 1900). Subsequently, the condition for patients 
suffering from anemia that could not be cured by supplements was dubbed ‘refractory 
anemia’. Chevalier is credited with establishing the concept of leukemia being linked to 
antecedent anemia, he proposed the term ‘odo-leukemia’ from the greek word ‘odo’ for 
‘threshold’ (Chevallier, 1942). Eventually ‘pre-leukemia’ became the term that was accepted 
in the literature for a disease condition that encompassed cytopenia and dysplastic features in 
one or more of the hematopoietic lineages in the bone marrow, having an increased risk of 
evolution to leukemia (Block and Jacobson, 1953; Hamilton-Paterson, 1949). The geneticist 
Hans Grüneberg discovered iron-laden precursors of red blood cells in both mice and man 
and dubbed them as siderocytes and sideroblasts (Doniach et al., 1943; Grüneberg, 1939). 
Some 15 years later, Sven-Erik Björkman published four cases of acquired idiopathic 
sideroblastic anemia and described the curious finding of ringsideroblasts (Björkman, 1956). 
In 1969 William Dameshek suggested to include these pre-leukemias under his umbrella of 
myeloproliferative diseases (Dameshek, 1951) but Harriet Gilbert recognized that some 
preleukemic cases were distinct from the classic myeloproliferative disorders. She coined the 
term “myelodysplastic disease” for pre-leukemic cases with lack of cell maturation (Gilbert, 
1970). It soon became apparent that some patients with preleukemia never developed 
leukemia and Fisher and colleagues suggested to favour “myelodysplasia” over 
“preleukemia” (Fisher et al., 1973). In 1982, the French-American-British (FAB) cooperative 
group suggested criteria for the myelodysplastic syndromes (Bennett et al., 1982). This 
milestone greatly enabled further investigations into the prognosis and management of the 
disease.  
 
2.2 EPIDEMIOLOGY 
MDS commonly occurs in older individuals with a slight male predominance. The median 
age at diagnosis is above 70 years in most studies (Ma et al., 2007; Nordic MDS Group, 
2017; Smith et al., 2011). 
The exact incidence of de novo MDS has been difficult to determine. While MDS in Sweden 
has been included in cancer registries since the 1980s, the diagnosis of MDS is excluded from 
cancer registries in some countries. Moreover, many older individuals with cytopenias are 
incompletely evaluated in the case of significant comorbidities. The single most important 
risk factor for development of MDS is aging. MDS increases exponentially with age - while 
the yearly incidence in people below 30 years of age is around 0.1-0.4 per 100 000, people in 
their 80s have an incidence of 30 per 100 000.  
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The vast majority of primary (de novo) MDS cases are viewed as idiopathic in nature, 
although the causes are beginning to be elucidated and constitutes the topic of this thesis. 
About 10-15% of MDS are secondary or therapy-related. Environmental factors such 
radiation and chemical exposure or previous treatment with cytotoxic drugs are highly 
associated with MDS. In clinical practice it can be difficult to establish a causal link between 
exposure to a particular substance and the development of MDS, but findings of particular 
chromosomal aberrations (chromosomes 5 and 7), complex karyotype (>3 acquired 
chromosome abnormalities, and mutations in TP53 suggest secondary rather than de novo 
MDS. 
 
2.3 CLINICAL PRESENTATION AND MORPHOLOGICAL DIAGNOSIS 
The typical clinical presentation of a patient with MDS is one of unexplained anemia, usually 
macrocytic, with or without additional cytopenias. Symptoms of anemia include fatigue, 
pallor, weakness, dyspnea, cognitive impairment and headache (Foucar et al., 1985; Goldberg 
et al., 2010; Jansen et al., 2003; Meyers et al., 2005). The most pervasive symptom is fatigue 
which can be out of proportion to the degree of anemia (Abel et al., 2016; 2014). In a 
minority of patients, myelodysplasia manifests itself as sole thrombo- or leukocytopenia, with 
bleedings or infections as the initial presenting symptoms. Even more rarely, patients present 
initially with autoimmune manifestations, e.g., vasculitis, arthritis and pulmonary effusions 
(Billström et al., 1995; Giannouli et al., 2004).  
Two hallmarks characterize MDS: firstly, abnormal cell morphology (dysplasia) and 
secondly, quantitative changes in one or more hematopoietic lineages (cytopenias). 
Performing complete blood counts almost invariably reveals a macrocytic or normocytic 
anemia while neutropenia and thrombocytopenia are more variable. Up to half of the patients 
present with pancytopenia at time of diagnosis. 
The diagnostic evaluation of patients suspected of having MDS begins with family and past 
medical history and physical examination, followed by complete blood counts, examination 
of the peripheral blood smear and bone marrow aspirate and biopsy as well as cytogenetic 
studies. Additional laboratory test are also performed to rule out other disorders that can 
mimic MDS (Steensma, 2012). Medications, alcohol abuse, nutritional deficiencies (e.g., 
vitamin B12, folate, iron) can all lead to morphological dysplasia. Furthermore, HIV 
infection and immune-mediated cytopenia need to be ruled out. 
Evidence of dysplasia in white and red blood cells can usually be demonstrated in the 
peripheral blood smear while the morphology of platelets is usually normal. Figure 2 
illustrates and summarizes the morphologic abnormalities in MDS. 
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While a blood smear may suggest MDS, examination of the bone marrow aspirate is essential 
for the diagnosis. It can reveal dysplasia in one or more lineages, with significant dysplasia 
being defined by presence of dysplastic features in at least 10% of hematopoieitic precursor 
cells of a particular lineage (binucleate erythroid precursors, megaloblastoid erythroid 
maturation, ring sideroblasts, hypolobulation and hypogranulation of neutrophils, and small 
megakaryocytes with abnormal segmentation of their nuclei).  
The absolute numbers of neutrophils and platelets are poorly correlated with the risk for 
infection and bleeding. However, the cellular dysfunction is often associated with the 
dysplasia itself, e.g., hypogranular neutrophils demonstrate impaired phagocytosis and 
microbicidal activity (Boogaerts et al., 1983) and platelet dysfunction is due to lack of 
expression of procoagulant molecules (Manoharan et al., 2002).  
According to the criteria of the Word Health Organization (WHO) (Arber et al., 2016), at 
least 500 nucleated cells and 20 megakaryocytes have to be assessed. Based on this 
evaluation, the percentage of blasts in the marrow can be determined, and the morphology of 
blasts and other cells can be cytologically assessed. Impaired maturation of myeloid cells is 
usually apparent. While the percentage of granulocytic precursors is variable, it is decreased 
more often than increased. Sometimes, maturation arrest can occur, usually at the myelocyte 
stage. Cytoplasmic maturation may progress more rapidly than the nucleus.  
Figure 2. Representative examples of morphologic abnormalities of myelodysplasia. Reproduced from 
(Cazzola et al., 2013) with permission from Blood. © the American Society of Hematology.  
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Examination of the bone marrow core (so-called trephine) biopsy provides important 
additional information, namely, the degree of cellularity, morphology of megakaryocytes, 
presence of fibrosis and overall architecture. 
Another method increasingly used in the evaluation of patients with suspected MDS is flow 
cytometry. While exceptionally suited for the detection of abnormal cell populations due to 
their aberrant expression of surface markers, it is currently viewed as an additional method 
and should be interpreted in the context of morphology of the bone marrow (Kern et al., 
2013; 2010; van de Loosdrecht et al., 2009; 2008; Wells et al., 2003). 
Cytogenetic studies on the other hand are currently essential in the evaluation of MDS. If 
morphologic assessment of the marrow proves to be equivocal, the finding of a cytogenetic 
abnormality can support the diagnosis (Arber et al., 2016). The importance of karyotypic 
abnormalities is discussed in more depth in the chapter on the molecular genetics of MDS. 
 
 
2.4 CLASSIFICATION 
The importance of the initial classification of MDS based on the FAB criteria put forward in 
1982 cannot be overstated, as this classification paved the way for subsequent studies on 
prognosis and clinical management of the disease (Bennett et al., 1982). Five morphological 
subgroups were initially defined, based largely on percentages of bone marrow blasts and 
ringsideroblasts, i.e., refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with 
excess of blasts (RAEB), chronic myelomonocytic leukemia (CMML), and RAEB in 
transformation (RAEB-t). To distinguish MDS from AML, the level of bone marrow blasts 
was set at 30%.  
Refining these initial criteria almost 20 years later, the WHO proposed their guidelines for the 
classification of MDS, taking into consideration the number of dysplastic cell lines, blast 
percentage, presence of ringed sideroblasts, myeloproliferative features, number of 
monocytes in blood and deletion of chromosome 5. Revisions of the WHO classification 
were published in 2008 and 2016 (Arber et al., 2016; Swerdlow, 2008). This most recent 
iteration incorporates further refinements of morphologic assessment, cytopenic evaluation as 
well as genetic information (Table 1). 
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Table 1. Peripheral blood and bone marrow findings and cytogenetics of MDS. Repodruced from (Arber 
et al., 2016) with permission from Blood. © the American Society of Hematology. 
 
The natural course of MDS is quite variable amongst individual patients, reflecting in part 
different patient characteristics (e.g. age, previous exposure to chemotherapy) as well as 
known and unknown differences in pathogenesis of different MDS subtypes. While the 
classification systems primarily based on pathology such as the FAB and WHO have been 
invaluable for diagnosis they have their limitations in terms of prognosis. Thus, the existing 
classification schemes were further refined, including age and sex, morphologic features, 
blast percentages, presence of cytopenias, cytogenetic abberations, clinical characteristics, 
and transfusion requirements as additional variables. 
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2.5 PROGNOSIS 
The old term “pre-leukemia” may be over-simplifying and in fact be a deceiving concept 
since the majority of patients with MDS do not transform into AML - rather, they succumb to 
the sequelae of bone marrow failure, e.g., infection, bleeding and symptomatic anemia. 
The natural course of MDS is quite variable amongst individual patients, reflecting in part 
different patient characteristics (e.g. age, previous exposure to chemotherapy) as well as 
known and unknown differences in pathogenesis of different MDS subtypes. While the 
classification systems primarily based on pathology such as the FAB and WHO have been 
invaluable for diagnosis they have their limitations in terms of prognosis. Since the treatment 
recommendations rely on an accurate prognostic stratification, it is thus necessary to stratify 
patients according to their risk in order to be able to assess an individual patient’s prognosis 
and make therapeutic decisions. Several investigators have proposed prognostic scoring 
systems that divide patients into lower and higher risk subgroups, usually incorporating 
clinical as well as pathological information. Each system has its strengths and limitations but 
most importantly, all prognostic systems explain only a minor part of the observable 
variability in outcome. By initially observing an individual’s disease course - as opposed to 
abruptly starting therapy - one can glean important information about tempo and prognosis 
for the particular patient. 
Based on number of cytopenias, percentage of bone marrow blasts and karyotype Greenberg 
et al. established the “International Prognostic Scoring System” (IPSS) for MDS in 1997 
(Greenberg et al., 1997). Based on a multivariate analysis of a study cohort consisting of 
more than 800 MDS patients from the United States, Europe and Japan, four risk categories 
were defined which predicted risk of evolution to AML as well as overall survivial: Low, 
Intermediate-1 (Int-1), Intermediate-2 (Int-2), and High-risk. Upon stratification according to 
age, there was a significantly longer overall survival in patients below 70 years of age, but 
only in patients belonging to Low and Int-1 risk categories. In contrast, there was no 
association of age and survival in the higher risk categories, possibly because of high disease 
related mortality. The risk of AML progression was not associated with age. 
To calculate the IPSS score, values from zero to two are determined for each of three 
variables according to the Table2. The IPSS score is calculated as the sum of each of these 
three values. It defines four risk groups for both overall survival as well as transformation 
into AML: low (0 points), intermediate-1 (0.5-1 points), intermediate-2 (1.5-2 points) and 
high (2.5-3). The IPSS also stratified survival according to patient age. While the median 
survival of low risk patients strongly depended on age (see table), the median survival of high 
risk patients was independent of age (between 4-6 months). 
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Table 2. The 1997 International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes. 
Original publication by (Greenberg et al., 1997). Table reprinted from (Steensma, 2015), with 
permission from Elsevier. 
 
The revised IPSS (IPSS-R) was published in 2012, it incorporated five rather than three 
subgroups based on cytogenetics, divided marrow blast percentage 5% into two sub-groups 
and expanded assessment of different cytopenias (Greenberg et al., 2012).  
To calculate the revised IPSS-score, individual scores from zero to four are determined for 
each of five variables (Table 3): 
1. Bone marrow blast percentage 
2. Karyotype 
3. Hemoglobin level 
4. Platelet count 
5. Absolute neutrophil count 
The IPSS-R score is calculated from the sum of these five values. It defines five risk groups 
for both overall survival and AML progression. Patient age is an optional variable which can 
be incorporated to predict overall survival, but not evolution to AML. 
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Table 3. The 2012 Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic 
Syndromes. Original publication by (Greenberg et al., 2012). Table reprinted from (Steensma, 2015), 
with permission from Elsevier. 
 
It is worth noting that the IPSS is based on data from MDS patients at diagnosis and can 
therefore not be used during an individual’s disease course or at time of progression. 
Therefore, Malcovati et al proposed a time-dependent prognostic scoring system based on the 
WHO classification which allowed repeated assessment of an individual’s prognosis at any 
time point of the disease including at time of progression. This WHO-classification based 
prognostic scoring system (WPSS) is based on the different WHO subgroups, karyotype and 
incorporates transfusion dependency (Malcovati et al., 2007). The latter is an independent 
negative prognostic factor. The WPSS defines five prognostic groups on a spectrum from 
very low to very high risk. Patients over 70 years and with very low risk MDS have a similar 
overall survival as the general population. Moreover, the presence of fibrosis and co-
morbidity have also been identified as independent negative factors.  
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Taking into account the patient’s age, comorbidities, and functional status, and based on the 
predicted risk of disease, clinicians are able to tailor therapeutic recommendations to each 
patient’s situation. 
 
 
2.6 TREATMENT 
2.6.1 Hematopoietic Cell Transplantation 
Currently, the only potentially curative treatment for MDS is allogeneic hematopoietic cell 
transplantation (HCT) (Parmar et al., 2011). In 1956, E Donnall Thomas performed the first 
successful transplantation of bone marrow from an identical twin into a patient with leukemia 
after prior radiotherapy. After other reports of failure (Rozman et al., 1978), Bhaduri et al. 
reported the first case of successful transplantation for a patient with MDS in 1979 (Bhaduri 
et al., 1979). By the early 1980s, this treatment modality had become established at several 
large cancer centers (Storb, 2003).  
Significant advances in bone marrow / hematopoietic cell transplantation have been made 
during the last decades: selection of donors, cell source and post-transplant immuno-
suppression have all undergone significant developments (Giralt, 2005). Collectively, this has 
led to a large decrease in transplantation related mortality (TRM) (Gyurkocza et al., 2010; 
Storb et al., 2001). 
Unfortunately, given that the median age of patients at time of their MDS diagnosis is greater 
than 70 years, only a minority of patients are eligible for HCT, mainly due to comorbidities 
and reduced physical fitness (Deeg and de Lima, 2013). While this therapeutic modality has 
been used in less than 10% of the patients, its use has recently increased (de Witte et al., 
2017; Gyurkocza and Deeg, 2012; Kröger, 2012). The majority of MDS patients >70 years 
nowadays receive reduced-intensity conditioning (RIC) before the infusion of allogeneic 
hematopoietic cells (Koreth et al., 2013), thus relying upon an immunological attack - the so-
called graft-versus-leukemia (GVL) effect - of the infused cells to eradicate neoplastic clones 
of MDS cells. In general, the outcomes for MDS patients using myeloablative versus 
reduced-intensity conditiong are similar. However, reduced-intensity conditioning is inferior 
to myeloablative conditioning in terms of a higher relapse rate (Luger et al., 2012; Martino et 
al., 2006), while the risk for transplantation-related mortality is lower (Deeg et al., 2012; 
Koenecke et al., 2015). In the best clinical scenario, younger patients less than 40 years of age 
can experience long-term disease free survival in more than 50% of cases. In reality, only 
about one-third of MDS patients are considered cured - the 5-year overall as well as relapse-
free survival rates after transplantation for MDS have been reported to be around 33% with 
strong inverse correlation to the IPSS-R score (Koenecke et al., 2015).  
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Thus, the current Nordic guidelines recommend that all MDS patients who are potential 
candidates for a transplant should be evaluated by a physician with expertise in hematopoietic 
cell transplantation early in the course of their disease (Nordic MDS Group, 2017). 
Therapeutic decisions are currently guided by overall clinical assessment and risk 
stratification systems (IPSS-R and/or others). The prognostic evaluation should determine the 
particular therapy for each individual patient. The goal for lower-risk patients are mainly 
focused on quality of life and symptom control. For higher-risk patients delay of disease 
progression and extension of survival have been achieved with azacitidine. Previous analyses 
based on mathematical modelling suggested that higher-risk patients derive a net gain of life 
from referral for HCT soon after their diagnosis while lower-risk patients benefit from 
waiting before being referred for HCT (Cutler et al., 2004; Koreth et al., 2013). 
 
2.6.2 Supportive Care 
About 40% of lower-risk patients and 60-80% of higher-risk patients are dependent on red 
blood cell transfusions (Cazzola et al., 2008; Hellström-Lindberg and Malcovati, 2008; 
(Nordic MDS Group, 2017). The requirement for regular transfusions have been associated 
with inferior survival compared to patients who do not require transfusions. Likely 
explanations are that this simply indicates more severe hematopoietic failure or that the 
increased transfusion frequency itself is harmful due to iron overload or additional 
mechanisms (Malcovati, 2007). 
In patients with evidence of iron overload and a relatively good prognosis therapy with the 
iron chelators deferoxamine or deferasirox can be considered, although there are currently no 
randomized controlled studies that have demonstrated a benefit from iron chelation in MDS 
(Nordic MDS Group, 2017). 
After infections, the second most common cause of morbidity and mortality is bleeding 
(Kantarjian et al., 2007). Supportive platelet transfusions can decrease bleeding risk, 
however, patients frequently develop alloimmunization with repeated platelet transfusion. 
While transfusion support can ameliorate symptoms and thus improve quality of life, there 
appears to be no direct impact on survival (Nachtkamp et al., 2009). 
 
2.6.3 Hematopoietic Lineage Growth Factors 
The erythropoesis-stimulating agents epoetin and darbepoetin (EPO) yield erythroid response 
rates in up to 50% of patients and are recommended as first-line treatment for the anemia of 
lower-risk MDS (Hellström-Lindberg and Malcovati, 2008; Malcovati et al., 2013; Nordic 
MDS Group, 2017). The response rate is inversely correlated with the individual’s 
endogenous erythropoietin levels. While patients with high serum erythropoietin levels rarely 
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respond, an initial trial for 2-3 months is appropriate in patients with serum erythropoietin 
levels of 500 U/L or less (Buckstein et al., 2017; Hellström-Lindberg et al., 2003). 
Combining EPO with granulocyte colony-stimulating factor (G-CSF) has been shown to be 
superior to EPO alone in RARS patients (Jädersten et al., 2008; Park et al., 2008), likely due 
to synergistic effects via inbition of erythroid apoptosis (Tehranchi et al., 2003).  
While G-CSF and GM-CSF have been shown to increase the number of neutrophils, they 
have failed to demonstrate an increase in survival (Vadhan-Raj et al., 1987). Rather, one 
study found G-CSF to be associated with shorter survival in patients with excess blasts, 
however, progression to AML was similar between the two groups. The current 
recommendation is to reserve G-CSF for patients with recurrent infections while being 
mindful of the fact that simply increasing the number of circulating neutrophils does not help 
if these cells are dysfunctional. 
The past few years have witnessed an increased usage of thrombopoietin (TPO) receptor 
agonists in MDS (Brierley and Steensma, 2015). While formally approved solely for immune 
thrombocytopenia, eltrombopag and romiplostim have been used in MDS, owing to the fact 
that some MDS patients also have immune-mediated thrombocytopenia (Giagounidis et al., 
2014). Analogous to EPO-treatment, patients who respond best have endogenous TPO levels 
less than 500 pg/L and an infrequent requirement for platelet transfusions {Sekeres:2014ck}.  
Lastly, a main staple in supportive therapy is e-aminocaproic acid, an antifibrinolytic drug 
that has been shown to decrease bleeding in thrombocytopenic patients (Salacz et al., 2007). 
 
2.6.4 Immunomodulatory drugs 
Based on findings that autoreactive T cells can play a role in suppressing hematopoiesis 
(Epling-Burnette et al., 2007), treatments similar to those used for aplastic anemia, e.g., 
cyclosporine and antithymocyte globulin were evaluated in patients with MDS (Parikh et al., 
2012). However, response to treatment was heterogenous (Saunthararajah et al., 2003; Sloand 
et al., 2008), with benefits mostly seen in those patients with the most benign disease 
expressions (Molldrem et al., 1997; 2002).  
Thalidomide was another agent evaluated for its immunomodulatory effects together with its 
potential for inhibition of neoangiogenesis. While up to 25% of patients showed a favorable 
response, the adverse events of sedation, constipation and neuropathy were quite significant 
(Raza et al., 2001). Based on these findings, the second-generation immunomodulatory drug 
lenalidomide was evaluated in lower-risk patients (List et al., 2005). A subsequent study (List 
et al., 2006) estasblished that lenalidomide is most effective in low- to int-1 risk patients with 
deletion of chromosome 5q31. In this subgroup, two-thirds achieve transfusion independence, 
an increase in hemoglobin level and a median response duration of more than 2 years 
(Fenaux et al., 2011). Moreover, cytogenetic remission were seen in up to 50% of patients. In 
patients with normal karyotype or chromosomal abnormalities other than 5q, responses are 
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less frequent (Raza et al., 2008). Only 25% become transfusion independent and the median 
response duration is less than a year. Myelosuppression is lenalidomide's most common 
adverse effect and patients with thrombocytopenia, excess blasts or complex karyotypic 
abnormalities are unlikely to respond to lenalidomide. 
 
2.6.5 Hypomethylating agents (DNMT inhibitors) 
The transcription of genes is affected by epigenetic changes. An important epigenetic 
modification is the process of DNA methylation where cytidine residues are covalently 
modified by enzymes that add methyl-groups. These enzymes are called DNA 
methyltransferases. Azacitidine and decitabine are nucleoside analogues of cytosine and 
inhibit DNA methyltransferase I. Azacitidine decreases methylation of DNA and is thought 
to reverse gene silencing (Issa and Kantarjian, 2009). In addition, these analogues induce 
DNA damage similar to cytarabine and other nucleoside analogues (Issa, 2013). Azacitidine 
was evaluated in higher-risk patients (int-2 and high-risk, (Fenaux et al., 2009)). Compared to 
either best supportive care, low-dose cytarabine or AML-induction therapy, the azacitidine 
group exhibited a significant increase in median survival (24 months for azacitidine vs. 15 
months for patients in other groups). While only a minority of patients (16%) achieved a 
complete response rate, this is not a requirement for achieving a survival benefit. The clinical 
response to hypomethylating agents might not be readily apparent as responses might be slow 
(Gore et al., 2013). Thus, an adequate therapeutic trial of azacitidine consists of 6 treatment 
cycles. The most common adverse effects, i.e., thrombocytopenia and neutropenia, are in 
clinical practice difficult to distinguish from the underlying disease (Nordic MDS Group, 
2017).  
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3 THE GENETIC BASIS OF MDS 
3.1 RECURRENT CYTOGENETIC ABNORMALITIES  
At time of diagnosis, about 50% of patients with MDS have clonal chromosomal 
abnormalities (Billström et al., 1988; Haase et al., 2007; Mallo et al., 2011; Mauritzson et al., 
2002; Sole et al., 2000; 1992). These chromosomal changes can manifest as structural 
abnormalities involving one chromosome (e.g., inversion, interstitial deletion), numerical 
changes (e.g., monosomy or trisomy) or be a balanced translocation between two 
chromosomes. About 15% of patients have multiple abnormalities and thus exhibit complex 
karyotypes. During the course of the disease, additional chromosomal aberrations may 
develop on top of previous ones or emerge in patients with no previous karyotypic 
abnormality. These changes are invariably associated with poor prognosis and progression to 
acute leukemia (Bochtler et al., 2015). However, none of the chromosomal abnormalities are 
specific for MDS and are also found in other myeloid diseases. 
 
Table 4. Frequency and median survival of cytogenetic prognostic subgroups. Data is sorted by 
frequency of cytogenetic aberration. This table is based on original data found in table 4 from (Haase 
et al., 2007). 
 
  
Anomaly Frequency (%)
Median 
survival 
(mo)
Anomaly Frequency (%)
Median 
survival 
(mo)
Anomaly Frequency (%)
Median 
survival 
(mo)
No (normal karyotype) 49.5 53.4 +8, NC 5 23 Complex, all 13.4 8.7
del(5q), NC 10.7 77.2 +8, isolated 3.8 22 Four to 6 abnormalities 5.3 9
del(5q), isolated 8.2 80 -7, NC 3.2 14 More than 6 abnormalities 3.9 5
-Y, sole 3.5 36 Any 3 abnormalities 2.8 17.1 t(5q), NC 0.4 4.4
-Y, NC 2.7 39 -7, sole 2.3 14
del(5q), +1 2.5 47 del(11q), NC 0.9 26.1
del(20q), NC 2.2 71 -7,+1 0.9 14.4
del(20q), isolated 1.9 71 del(7q), isolated and NC 0.6 19
+8,+1 1.2 44 del(11q), isolated 0.6 15.9
+21, NC 1.1 100.8 t(11q23), NC 0.5 20
del(12p), NC 0.8 108 Rea 3q, NC 0.5 19.9
+21, +1 0.8 80 +19, NC 0.4 19.8
t(1q), NC 0.6 34.7 -5,NC 0.4 14.6
t(7q), NC 0.6 34.7
-X, NC 0.5 56.4
t(11q),NC 0.5 32.1
-21, NC 0.5 32
del(9q), NC 0.4 NR
del(15q), NC 0.4 NR
t(15q),NC 0.4 NR
-Y,+1 0.4 84.6
+ 1/+1q, NC 0.4 34.7
NC indicates noncomplex karyotype; and NR, not reached. 
Good-prognosis cytogenetics Intermediate-prognosis cytogenetics Poor-prognosis cytogenetics
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. -7, NC 3.2 14 More than 6 abnormalities 3.9
. Any 3 abnormalities 2.8 17.1 t(5q), NC 0.4 .
. -7, sole 2.3 14
. del(11q), NC 0.9 26.1
. -7,+1 0.9 14.4
. del(7q), isolated and NC 0.6 19
. del(11q), isolated 0.6 15.9
. . t(11q23), NC 0.5 20
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t , . . -5,NC 0.4 14.6
t( ), . .
- , . .
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del(15q), 0.4
t(15q), 0.4
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- r i  t ti Inter ediate-prognosis cytogenetics Poor-prognosis cytogenetics
Anomaly Frequency (%)
Median 
survival 
(mo)
Anomaly Frequency (%)
Median 
survival 
(mo)
Anomaly Frequency (%)
Median 
survival 
(mo)
No (normal karyotype) 49.5 53.4 +8, NC 5 23 Complex, all 13.4 8.7
del(5q), NC 10.7 77.2 +8, isolated 3.8 22 Four to 6 abnormalities 5.3 9
del(5q), isolated 8.2 80 -7, NC 3.2 14 More than 6 abnormalities 3.9 5
-Y, sole 3.5 36 Any 3 abnormalities 2.8 17.1 t(5q), NC 0.4 4.4
-Y, NC 2.7 39 -7, sole 2.3 14
del(5q), +1 2.5 47 del(11q), NC 0.9 26.1
del(20q), NC 2.2 71 -7,+1 0.9 14.4
del(20q), isolated 1.9 71 del(7q), isolated and NC 0.6 19
+8,+1 1.2 44 del(11q), isolated 0.6 15.9
+21, NC 1.1 100.8 t(11q23), NC 0.5 20
del(12p), NC 0.8 108 Rea 3q, NC 0.5 19.9
+21, +1 0.8 80 +19, NC 0.4 19.8
t(1q), NC 0.6 34.7 -5,NC 0.4 14.6
t(7q), NC 0.6 34.7
-X, NC 0.5 56.4
t(11q),NC 0.5 32.1
-21, NC 0.5 32
del(9q), NC 0.4 NR
del(15q), NC 0.4 NR
t(15q),NC 0.4 NR
-Y,+1 0.4 84.6
+ 1/+1q, NC 0.4 34.7
Good-prognosis cytogenetics Intermediate-prognosis cytogenetics Poor-prognosis cytogenetics
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Importantly, irrespective of blast count, AML is diagnosed if any of the following cytogenetic 
abnormalities are present:  
• t(8;21)(q22;q22): RUNX1-RUNX1T1 (previously AML1-ETO) 
• inv(16)(p13.1q22) or t(16;16)(p13.1;q22): CBFB-MYH11 
• t(15;17)(q22;q21.1): PML-RARA 
The karyotypic abnormalities that are most commonly found in MDS are del(5q), del(7q) or 
monosomy 7 (-7), trisomy 8 (+8), del(20q) as well as loss of the Y chromosome (Billström et 
al., 1988; Haase et al., 2007). Although the same cytogenetic lesions also occur in de novo 
AML, the balanced translocations typical for AML are uncommon in MDS (Mauritzson et 
al., 2002). Instead, the chromosomal abnormalities in MDS are usually unbalanced, 
indicating gain or loss of chromosomal material. In therapy-related MDS/AML cytogenetic 
abnormalities are even more prevalent, as up to 80% have chromosomal aberrations, in 
particular deletions of chromosomes 5 and 7. Deletion of the long arm of chromosome 5 with 
or without additional karyotypic abnormalities is not only the most frequent chromosomal 
aberration, it is the only one constituting its own entity in the WHO classification (Arber et 
al., 2016). 
Despite the fact that other chromosomal abnormalities in MDS are not associated with 
specific clinical or morphological subsets using the WHO classification system, they do play 
a substantial role in the pathogenesis and prognosis and have a major impact in the clinical 
management of patients. 
 
3.2 RECURRENTLY MUTATED GENES 
The recent advances in inexpensive high-throughput genome sequencing technologies have 
enabled the discovery of genetic lesions that drive the pathogenesis of the majority of human 
cancers (Vogelstein et al., 2013), including the myelodysplastic syndromes. 
Based on panels of genes that were previously found to be mutated in other myeloid diseases, 
a number of studies during the last years have described the mutational landscape of somatic 
point mutations in MDS (Bejar et al., 2011; Haferlach et al., 2014; Papaemmanuil et al., 
2013; Yoshida et al., 2011). Based on current data, up to 90% of patients bear mutations in at 
least one recurrently mutated gene and it is believed that the remaining 10% of patients have 
mutations in genes yet to be identified. 
MDS is the result of the sequential accrual of somatic mutations in hematopoietic stem cells. 
Based on calculations, these stem cells amass approximately 1.3 mutations in exons every 
decade (Welch et al., 2012) but the majority of these are innocent bystanders with no 
functional alteration (Mardis et al., 2009). However, this calculation presumes that the rate of 
mutation is constant - in reality, the process of mutation accrual could be dynamic as one 
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mutation might affect the acquisition of 2nd or 3rd hits and so forth (Papaemmanuil et al., 
2013). The spectrum of recurrent somatic mutations in MDS and other myeloid diseases can 
be organized into several groups based on their biologic pathways. 
 
3.2.1 Mutations in splicing factors 
The alternative splicing of pre-mRNA is a hallmark of eukaryotes that enables the generation 
off different proteins from the same gene. Interestingly, aberrant alternative splicing is also 
one of the hallmarks of cancer (Lawrence et al., 2014).  The seminal study by Yoshida et al. 
identified recurrent mutations in genes that are part of the  spliceosome in up to 60% of cases 
of MDS (Yoshida et al., 2011).   
 
Table 5. Most common driver genes in patients with MDS and MDS/MPN. Reproduced from (Cazzola et 
al., 2013) with permission from Blood. © the American Society of Hematology. 
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The mutations in SF3B1, U2AF1 and SRSF2 are invariably found within defined hotspots of 
these genes leading to loss of function, altering the  operation of the splicing machinery 
(Graubert et al., 2011; Inoue et al., 2016; Papaemmanuil et al., 2011).  The most common 
mutation within the splicing component affect SF3B1 and these mutations occur in up to 90% 
of MDS patients with ringssideroblasts (RARS) (Malcovati et al., 2015; 2011). In this 
context, SF3B1 mutations are associated with a good prognosis. Current data suggest that the 
ringsideroblast phenotype is the result of aberrant splicing of genes central in iron 
homeostasis (Conte et al., 2015). The second most frequent splicing factor mutation in MDS 
is SRSF2. In the overlap syndromes of MDS/MPN this gene is also commonly mutated. It has 
been shown that mutations in SRSF2 altered binding of the protein to splice enhancers and 
that this subsequently leads to mis-splicing of several important downstream genes one of 
which is EZH2 (Kim et al., 2015). In 10 to 15% of MDS cases mutations are found in U2AF1 
(Graubert et al., 2011). Loss-of-function is reported to lead to increased exon skipping (Ilagan 
et al., 2015; Przychodzen et al., 2013). SRSF2 and U2AF1 have not been associated with a 
similar favourable prognosis as SF3B1. Despite the aforementioned findings, no single mis-
spliced isoform has hitherto been implicated in the pathogenesis of MDS. Moreover, studies 
using mouse models of splicing genes have not yielded similar patterns of altered splicing, 
neither between mice and men nor between individual mice (Kim et al., 2015; Kon et al., 
2017; Mupo et al., 2017; Obeng et al., 2016). Perhaps the role that these mutations play in 
MDS pathobiology is unrelated to their known function within the splicing machinery.  
 
3.2.2 Epigenetic regulators 
Another set of genes found to be recurrently mutated in MDS affect genes that are involved 
in epigenetic regulation (Shih et al., 2012). Epigenetic regulation is the result of post-
translational modification of either histones or the DNA itself. 
 
3.2.2.1 Histone modification 
The tails of histones can be covalently modified by enzymes, leading to changes in the 
structure of chromatin and affecting the binding of protein involved in gene regulation. 
Amongst the central regulators of transcriptional silencing in development are the PRCs 
composed of two separate protein complexes, PRC1 and PRC2. Their action on histones H2A 
and H3 results in the compaction of chromatin (Cao et al., 2002; Francis et al., 2004; Wang et 
al., 2004). Genes that are part of both protein complexes have been found to be mutated in 
MDS .  
Mutation in two components of PRC1, i.e., BCOR and BCORL1, have been shown to be 
recurrently mutated in 5% of MDS cases and found to portend an unfavorable prognosis (Cao 
et al., 2016; Damm et al., 2013; Gao et al., 2012; Gearhart et al., 2006; Huynh et al., 2000). 
EZH2 is mutated in about 5% of MDS patients, the resulting protein is part of the catalytic 
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subunit of PRC2. Studies in transgenic mice have confirmed that loss of Ezh2 results in MDS 
(Sashida et al., 2014).  
ASXL1 is in itself not part of the PRC but has been shown to indirectly affect PRC2 leading to 
deubiquitylation of histone H2A (Abdel-Wahab et al., 2012; Scheuermann et al., 2010).  
Approximately 20% of MDS patients have recurrent mutations in ASXL1 (Haferlach et al., 
2014), these mutations are confined to exons 11 and 12, leading to truncation of the protein 
and thus increasing its deubiquitylation (Abdel-Wahab et al., 2012; Balasubramani et al., 
2015). The findings that mutations in BCOR, EZH2 and ASXL1 have been shown to disrupt 
normal hematopoieitc differentiation offers an explanation for their putative role in dysplasia 
and cytopenia (Abdel-Wahab et al., 2012; Cao et al., 2016; Sashida et al., 2014). 
 
3.2.2.2 DNA methylation 
Regulatory regions of the DNA can either be accessible or inaccessible. Which state is 
favoured is largely controlled by the methylation of cytosines in repetitive CpG elements. 
DNA methyltransferases (DNMTs) add methyl groups while the TET family of proteins are 
responsible for demethylation via a mutistep process (Ko et al., 2015; Tahiliani et al., 2009; 
Yang et al., 2015). Approximately 15% of MDS cases exhibit mutations in DNMT3A leading 
to loss-of-function of the protein (Haferlach et al., 2014; Ley et al., 2010; Papaemmanuil et 
al., 2013; Walter et al., 2011). TET2 is one of the most frequently mutated genes (Haferlach 
et al., 2014), with 30% of mutations resulting in inactivation of the target protein (Okano et 
al., 1998). The state of hypermethylation of cytosines at enhancer sites is believed to repress 
several genes with important roles in myeloid differentiation (Kallin et al., 2012; Rasmussen 
et al., 2015; Yamazaki et al., 2015). DNMT3A and TET2 are both expressed in hematopoietic 
stem cells - in a complementary, interconnected, yin-and-yang kind of fashion - having 
essential roles in self-renewal and myeloid differentiation (Challen et al., 2011; Mayle et al., 
2015; Moran-Crusio et al., 2011; Zhang et al., 2016). 
It was initially puzzling how mutations in enzymes involved in the citric acid cycle play a 
role in the pathogenesis of MDS and leukemia. However, it was found that cells with 
mutations in IDH1 and IDH2 accumulated a novel oncometabolite, 2-hydroxyglutarate (2-
HG), instead of alpha-ketoglutarate (Dang et al., 2009; Ward et al., 2010; Xu et al., 2011). 2-
HG was shown to diffuse to the nucleus leading to inhibition of - amongst others - TET2 and 
thus also affecting DNA methylation (Lu et al., 2012). Mutations in IDH1 or IDH2 occur in 
~5% of patients with MDS (Haferlach et al., 2014). While the oncometabolite was shown to 
be sufficient to promote leukemogenesis, the effects were found to be reversible (Losman et 
al., 2013). This has led to the development of 2-HG inhibitors which are currently being 
evaluated in clinical trials. 
 
 24 
3.2.3 Cohesin complex 
An important part of DNA repair is the formation of a protein complex that holds together 
sister chromatids preventing the collapse of the replication fork thereby enabling DNA repair 
(Losada, 2014). This protein complex is made up of the co-called cohesins, STAG2, SMC3, 
SMC1A and RAD21. Taken together, inactivating mutations in cohesin genes are found in 
15% of MDS cases (Haferlach et al., 2014; Papaemmanuil et al., 2013). Perhaps somewhat 
surprisingly given their function, cohesin mutations have not been associated with 
chromosomal abnormalities (Thota et al., 2014). Rather, it is now believed that cohesin 
mutations lead to altered gene expression due to a failure to stabilize loops of DNA that 
normally facilitate the interaction of promoters and distant enhancers (Horsfield et al., 2007; 
Leeke et al., 2014; Marsman et al., 2014; Mazumdar et al., 2015; Viny and Levine, 2017). 
 
3.2.4 Transcription factors 
A small group of hematopoietic transcription factors have been found to be recurrently 
mutated in MDS. Taking clues from inherited bone marrow failure disorders, where germ-
line mutations in RUNX1, GATA2 and ETV6 had been linked to development of MDS and 
AML (Growney et al., 2005; Hahn et al., 2011; Zhang et al., 2015), these genes were also 
included in targeted sequencing panels for the study of MDS. Mutations in RUNX1 are often 
associated with severe thrombocytopenia (Owen et al., 2008), they occur in approximately 
10% of MDS cases (Haferlach et al., 2014). The protein forms the subunit of the core binding 
factor and is responsible for DNA-binding. Several target genes of RUNX1 have important 
roles in hematopoiesis (Ito et al., 2015).  
The zinc finger protein GATA2 is highly expressed in HSCs and was shown to be essential 
for normal hematopoietic differentiation (Tsai et al., 1994). Somatic mutations in GATA2 
account for only 1% of MDS cases (Haferlach et al., 2014). The transcription factor Wilms 
tumor protein WT1 has been shown to recruit TET2 to specific loci and is mutated in fewer 
than 5% of cases of MDS (Rampal et al., 2014; Wang et al., 2015). There are other 
transcription factors with mutation frequencies below 1%. 
 
3.2.5 Cell signaling genes 
Genes for components of cell signaling pathways were shown to be mutated in a host of other 
myeloid malignancies and were thus obvious candidated to study in MDS (Furitsu et al., 
1993; Kottaridis et al., 2001; Kralovics et al., 2005). Compared to AML, CMML or PV/ET, 
the frequencies with which these genes are mutated in MDS is quite low. Taken together, 
mutations in components of the MAPK pathway, e.g., NRAS, KRAS, NF1 and PTPN11, are 
the most prevalent in MDS, accounting for approximately 10% of MDS cases (Haferlach et 
al., 2014; Papaemmanuil et al., 2013). In general, most mutations in signaling pathway 
components lead to the constitutive activation of the protein product. Of note, these mutations 
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often occur late in the course of the disease in more aggressive subclones that signify the 
transition to secondary AML (Murphy et al., 2013; Takahashi et al., 2013). 
 
3.2.6 TP53 
The single most frequently mutated tumor suppressor gene amongst all human cancers is 
TP53 (Lawrence et al., 2014). In the clinical condition known as the Li-Fraumeni syndrome, 
humans are born with a single mutant allele of TP53 (Li and Fraumeni, 1969). These people 
have a drastically increased risk for many types of cancer, including MDS and AML. In 
patients with MDS, somatic mutations of TP53 are usually associated with low platelet 
counts, a high blast count, a complex karyotype and previous chemotherapy exposure. 
Initially thought of as a tumor promoting oncogene (hence the name, tumor protein 53), the 
groups of Vogelstein and Levine revealed its role as a tumor suppressor gene (Baker et al., 
1989; Finlay et al., 1989). 
p53 has been dubbed the "guardian of the genome" (Lane, 1992) given that it functions as a 
mediator of cellular stress. In the appropriate context, p53 increases pro-apoptotic genes and 
mediates cell cycle arrest (Lowe et al., 2004). Accumulation of additional genomic 
aberrations and chromosomal instability together with chemotherapy resistance observed in 
patients with inactivation of the p53 pathway are likely due to inadequate activation of the 
DNA damage response and loss of cell cycle arrest measures, respectively .  
Several earlier reports had demonstrated the negative prognostic impact of TP53 mutations in 
a number of hematological malignancies, including MDS (Horiike et al., 2003; Mori et al., 
1995; Nakai et al., 1994; Preudhomme et al., 1994; Sugimoto et al., 1993). Mainly seen in 
high-risk and secondary (therapy-related) MDS (Adamson et al., 1995; Christiansen et al., 
2001; Kaneko et al., 1995; Kita-Sasai et al., 2001; Kitagawa et al., 1994; Lai et al., 1995; 
Ludwig et al., 1992; Side et al., 2004), TP53 mutations occured frequently in the context of 
complex karyotypes, and have also been associated with disease progression and poor 
response to therapy (Padua et al., 1998; Wattel et al., 1994). In lower-risk MDS, on the other 
hand, TP53 mutations were rarely observed (Fidler et al., 2004; Iwasaki et al., 2008). 
However, these studies suffered from small sample size and the inherent low sensitivity 
associated with usage of conventional Sanger sequencing techniques. Using sensitive deep 
sequencing, our group previously reported TP53 mutations in approximately 20% of low-risk 
del(5q) MDS patients (Jädersten et al., 2011). These mutations were detected years before 
disease progression and conferred an increased risk of evolution to overt leukemia.  
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3.3  CLONAL HEMATOPOIESIS 
Cancer is now known to result from the stepwise accumulation of somatic mutations. 
However, it has been difficult to define the initial stages preceding the development of overt 
hematological malignancies.  
Recently, three studies provided evidence for somatic mutations in blood DNA by using 
existing datasets of exome sequencing on peripheral blood samples from collectively more 
than 30,000 patients without known hematological cancers (Genovese et al., 2014; Jaiswal et 
al., 2014; Xie et al., 2014). While somatic mutations are rare (less than 1%) in people under 
40, they increase with age, with frequencies up to 10% and 20% in patients over the age of 65 
and 90, respectively. The acronym CHIP for Clonal Hematopoiesis of Indeterminate Potential 
has been adopted to describe this phenomenon (Steensma et al., 2015). Individuals with 
detectable mutations usually had only a single mutation. The majority of driver mutations 
sustaining clonal hematopoiesis occurred was explained by mutations in only three genes: 
DNMT3A, TET2 and ASXL1. Additional recurrently mutated genes were: JAK2, TP53, 
SF3B1, CBL, SRSF2, GNAS, PPM1D, BCOR, and BCORL1. Driven by usually one of these 
somatic mutations, a single founding cell expands to a detectable clone. 
After the initial hit occurring in a single stem cell there seems to be a substantial expansion of 
the formed clone as median clone size was approximately 18% of the cells in the peripheral 
blood. However, the large clone size observed in this study is related to the sensitivity of the 
method used for mutation detection. Studying clonal hematopoiesis by deep targeted 
sequencing (coverage >1000x) identified a clone size of 3% (McKerrell et al., 2015). 
While previous studies had demonstrated that certain chromosomal translocations were 
transiently detected in healthy individuals (Müller et al., 1995), somatic mutations in clonal 
hematopoiesis seem to persist for years with no indication of spontaneous resolution. In a 
limited number of patients were follow-up analysis was possible, all somatic mutations 
persisted after 4-8 years (Jaiswal et al., 2014). Clonal hematopoiesis was a strong predictor 
for the development of hematological malignancy (Hazard ratio of ~12), confirming that the 
initial mutation forms a pre-malignant state. Direct evidence for the evolution from clonal 
hematopoiesis to hematologic malignancy was possible for two people who developed AML 
as the leukemic samples were found to contain the somatic mutations at high allele fractions 
(Genovese et al., 2014). 
Clonal hematopoiesis is now viewed as part of the natural evolution from a pre-malignant 
state to overt leukemia (Ding et al., 2012b; Jan et al., 2012; Sperling et al., 2017), shown in 
Figure 2. 
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Figure 2. The natural evolution from normal hematopoiesis to the pre-malignant state of CHIP to 
MDS that progresses to overt secondary AML. 
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4 CLONAL EVOLUTION AND CLONAL ORIGIN 
4.1 CLONAL EVOLUTION OF THE DISEASE 
During cancer progression malignant cells are faced with genetic and epigenetic, as well as 
microenviromental selective pressure. The reiterative process of clones that expand, diversify 
genetically and subsequent selection of clones leads to the increased heterogeneity of the 
primary cancer. In a landmark article, Peter Nowell suggested that cancer followed the 
example of evolution by natural selection as originally proposed by Darwin (Darwin, 1859; 
Nowell, 1976). He hypothesized that cancers evolve over time by the stepwise acquisition of 
genetic variation. The term clonal evolution describes this increase in complexity during the 
progression of cancer. For a more in-depth discussion of these important concepts the reader 
is referred to the fascinating articles by Greaves and Maley (Greaves, 2010; Greaves and 
Maley, 2012). 
 
 
Figure 3. Clonal evolution is influenced by selective pressure from constraints 
("bottlenecks") of intracellular events (genetic and epigenetic), the microenvironment or 
therapy. Original concept from (Nowell, 1976) and adapted from (Greaves, 2010). 
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4.1.1 The “good-old days” - the pre-sequencing era 
The concept that evolution of MDS occurs by clonal expansion at the expense of normal 
progenitors was formulated by Jacobson et al. based on experiments involving G6PDH 
isoenzyme analysis and cytogenetic studies in cultured CFU-C. They found that the 
proportion of cells expressing type A G6PDH correlated with a proportional decline of 
karyotypically normal metaphases (Jacobson et al., 1978). 
Studies using sequential cytogenetic analysis demonstrated that clonal evolution correlated 
with phenotypic evolution. The term clonal evolution is used in the sense of acquisition of 
additional karyotypic abnormalities. Several studies demonstrated that evolution of 
karyotypic abnormalities conferred an increased risk of transformation towards leukemia, 
with complex karyotypes, i.e., greater or equal to 3 karyotypic abnormalities within the same 
clone, being associated with the greatest risk (Anderson and Bagby, 1982; Ayraud et al., 
1983; Gold et al., 1983; Nowell, 1982; Streuli et al., 1980; Yunis et al., 1988).  
By comparison, secondary MDS usually progresses rapidly to AML and showed a 
predominance of hypodiploid clones with a complex karyotype (Pedersen-Bjergaard et al., 
1984; Rowley et al., 1981). Interestingly, no fixed cytogenetic abnormality could be 
specifically associated with leukemic transformation. Hence, it appears that a common 
phenotypic endpoint can be reached via a broad variety of chromosomal rearrangements.  
Importantly, evolution of karyotype was found to be neither necessary nor sufficient for 
leukemic progression, as evolution of karyotype was also observed in non-leukemic 
progression of phenotype with both hypoplastic and myeloproliferative states as possible 
outcomes in MDS (Mufti et al., 1982; Tomonaga et al., 1984). Conversely, progression to 
leukemia had also been demonstrated to occur in the absence of any chromosome 
rearrangement, indicating that karyotypic changes - while sometimes sufficient - are not 
necessary for development of leukemia (Tricot et al., 1985). 
 
4.1.2 The genomic days 
Modern day genomics have confirmed cancer to be a complex, adaptive system following 
Darwinian principles. It appears that most mutational processes act at the level of the DNA 
sequence. While in principle being purposeless genetic variation, mutations alter the cell’s 
fitness which underlies the selection of clones. By using a car-analogy, mutagenic lesions are 
classified as either ‘driver’ or ‘passenger’ depending on whether or not a relevant role in 
oncogenesis has been ascribed to the gene. 
By performing whole-genome sequencing of paired samples from bone marrow and skin in 
secondary AML patients, Walter and coworkers identified somatic mutations specific to 
secondary AML (Walter et al., 2012). Examination of bone marrow from the antecedent 
MDS stage revealed that founding clones with 180-660 mutations persisted at the secondary 
AML stage. Acquisition of additional, new mutations led to the formation of subclones 
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containg an ever-increasing number of mutations. Similar to what has been observed for de 
novo AML (Welch et al., 2012), the majority appeared to be passenger mutations randomly 
acquired during aging with no apparent causal role in MDS pathogenesis. 
In a follow-up study of 157 patients (Walter et al., 2013), 83% had at least one cytogenetic 
aberration or somatic mutation with 17 genes being significantly mutated. A founding clone 
and at least one subclone was observed in all cases. No single gene was found to be mutated 
exclusively in a founding clone or subclone. Thus, reiterating what had been observed by 
cytogenetic studies in the 1980s, these modern-day genomic approaches suggest that many 
genetic paths can lead to the initiation of MDS. 
By using whole genome sequencing and transplantation into immunocompromised mice, 
Klco and colleagues demonstrated that genetic clonal architecture in AML correlated with the 
functional heterogeneity (Klco et al., 2014). In general, the patient-specific clonal architecture 
of the bone marrow was well represented in the patients’ peripheral blood. Relapsing AML 
subclones could not be predicted by engraftment or recurring AML mutations. Moreover, the 
finding that the clonal architecture was not recapitulated in the xenografts suggested two 
important conclusions. Firstly, leukemic stem cells are likely also genetically heterogenous 
and secondly, the selective growth pressure that cells encounter in the microenvironment of 
the patient can not be approximated by xenotransplantation into murine microenvironments. 
Previous data from our own group in del(5q) patients had shown clonal heterogeneity related 
to small TP53-mutated subclones which predicted for an unfavourable outcome and that these 
subclones expanded with progression of the disease (Jädersten et al., 2011; 2009). 
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5 PATHOGENESIS OF THE 5Q-SYNDROME 
In 1974 van den Berghe et al described three patients with the clinical features of refractory 
anemia characterized by erythroid hypoplasia, megakaryocytes with hypolobated nuclei and 
normal to elevated platelet counts (Van den Berghe et al., 1974). All three patients had an 
interstitial deletion of the long arm of chromosome 5. After identification of the Philadelphia 
chromosome with the typical translocation of t(9;22), the sole deletion at 5q became the 
second example of a chromosomal aberration linked to a particular malignancy. The 5q- 
syndrome has been acknowledged as a distinct entity ever since the first iteration of the WHO 
classification of MDS.  
The 2016 WHO classification of MDS uses the identification off del(5q) or del(5q) plus one 
other cytogenetic abnormality with the exception of -7/del(7q) in the definition of the 5q- 
syndrome (Arber et al., 2016). It is recognized as a distinctive type of MDS with the typical 
patient being an older woman. The female predominance of 70% is in contrast to the male 
predominance in other forms of MDS. Median age at diagnosis is between 65-70 years of 
age. Typically, patients present with a macrocytic anemia, normal or elevated platelet counts 
and an absence of significant neutropenia.  
It has now been established that del(5q) leads to haploinsufficiency of a small number of 
genes (RPS14, CSNK1A1, APC, HSPA9, DIAPH1, DDX41, EGR1, NPM1, TIFAB) and two 
micro-RNAs (miR-145 and miR-146a). While point mutations in the remaining normal allele 
have been found in CSNK1A1 or DDX41, no other genes has been found to be deleted or 
mutated.  
In a seminal study using targeted short hairpin RNA (shRNA), RPS14 haploinsufficiency was 
found to lead to abnormal erythroid differentiation via blocking ribosomal RNA processing 
(Ebert et al., 2008). Subsequently, mouse models with conditional heterozygous inactivation 
of Rps14 phenocopied the macrocytic anemia seen in the 5q- syndrome (Barlow et al., 2010). 
This effect was shown to be p53 dependent and involve upregulation of components of innate 
immune signaling.  
An important gene central to the pathogenesis of the 5q-syndrome is the serine-threonine 
kinase CSNK1A1 (Schneider et al., 2014). In Csnk1a1-heterozygously deleted cells, 
expression of the gene product, i.e., CK1a, is approximately 50% and this leads to increased 
stem cell self-renewal via upregulation of the WNT pathway. In contrast, homozygous 
deletion of Csnk1a1, leads to accumulation of p53 with loss of the competitive advantage 
observed in the heterozygous state. The gene-dosage effect of CSNK1A1 is central to the 
understanding of the treatment response to lenalidomide in MDS with deletion of 5q. CK1a 
can be targeted for degradation by the ubiquitin ligase CRL4 upon interaction with its co-
factor CRBN. In the absence of lenalidomide, the affinity for CK1a is low. The binding of 
lenalidomide, on the other hand, results in a conformational change in CRBN increasing its 
affinity and thereby targeting CK1a for degradation via the ubiquitylation pathway (Krönke 
et al., 2015). The lower expression level of CK1a in del(5q) HSC lacking one copy of 
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CSK1A1 leads to a competitive advantage over normal HSC. Treatment with lenalidomide 
decreases CK1a levels in both normal and 5q-deleted HSC. While CK1a-levels drop below a 
critical threshold optimal for survival in CSKN1A1-heterozygous cells, wt-CSNK1A1 cells 
prevail and gain the competive advantage. 
The observation that p53 is somehow pathogenetically linked to deletion of chromosome 5q 
has recently been confirmed by a number of studies. The combined genetic approach of next-
generation sequencing and mass spectrometry-based genotyping reported TP53 as one of 
several predictors of poor survival in a large cohort of MDS patients (Bejar et al., 2011). 
Intriguingly, TP53 mutations seem to be particularly frequent in MDS and AML with 
complex karyotypes including del(5q) and are often associated with a short survival 
(Kulasekararaj et al., 2013; Sebaa et al., 2012). In multivariate analyses of secondary AML, 
TP53 was found to be an independent adverse prognostic factor for overall survival 
(Milosevic et al., 2012). Zemanova et al. reported del(5q) to be unstable and associated with 
different types of cryptic unbalanced chromosomal rearrangements (Zemanova et al., 2014). 
Recent mouse models suggest that loss of Tp53 activity in the context of haploinsufficiency 
of the del(5q) genes Apc and Egr1 are sufficient for malignant transformation into AML 
(Stoddart et al., 2014). Several lines of evidence now suggest that the complete clinical 
phenotype of del(5q) MDS is the result of combinations of several genes (Graubert et al., 
2009). 
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6 THE HEMATOPOIETIC MICROENVIRONMENT IN MDS 
The ordered differentiation of distinct cellular entities of the complete hematopoieitic 
hierarchy are influenced by a variety of supportive microenvironmental niches. The cellular 
components of these niches are unique to the differentiation stage of the hematopoietic cells. 
An emerging model suggests that hematopoietic and mesenchymal cells are intertwined in a 
symbiotic relationship, each at particular stages in their respective differentiation (Morrison 
and Scadden, 2014). Distinct components of each niche support the maintenance, 
proliferation and differentiation of HSCs. Related to the finding that HSCs constitute the cell 
of origin in MDS, a central question has been which niche cells influence HSCs. Some niche 
cells are spawned descendents from HSCs themselves, e.g., macrophages and 
megakaryocytes (Bruns et al., 2014; Winkler et al., 2010; Zhao et al., 2014). In addition, 
various stromal cells such as vascular endothelial cells lining the sinusoids, osteoblast, 
adipocytes and mesenchymal stem cells have all been shown to function as niche cells in the 
microenvironment of HSC by altering their function and differentiation (Calvi et al., 2003; 
Ding et al., 2012a; Kfoury and Scadden, 2015; Méndez-Ferrer et al., 2010; Zhang et al., 
2003). 
In mouse models the selective disruption of certain genes only in certain stromal elements 
was sufficient to induce abnormal differentiation of HSC and dysplastic features 
(Raaijmakers et al., 2010; Walkley et al., 2007). On the other hand, myeloid neoplasms such 
as CML have been shown to alter the bone marrow microenvironment (Schepers et al., 2013). 
While it is possible to induce MDS-like disease in mouse models solely by stromal defects, it 
remains to be investigated whether or not human MDS is caused by defects confined to the 
microenvironment or whether the intrinsic genetic and epigenetic alterations of HSCs in 
MDS are necessary constituents of the human disease. 
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7 AIMS OF THIS THESIS 
  
The overall aims of this thesis were to characterize hematopoietic stem cells and the 
microenvironment from MDS patients with deletions of chromosome 5q and to elucidate 
mechanisms underlying disease progression and response to treatment. 
 
Specific aims were as follows: 
 
I. To elucidate the nature of the disease-initiating cell  
 
II. Determine which mutations are associated with disease progression of lower-
 risk patients with deletion of chromosome 5q 
 
III. To study putative abnormalities in the microenvironment of patients with 
 del(5q) MDS 
 
 
For details about the protocols of the experiments, the reader is referred to the material and 
methods section of the individual papers. 
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8 SUMMARY OF RESULTS & DISCUSSION 
8.1 CHARACTERIZATION OF STEM AND PROGENITOR CELLS IN DEL(5Q) 
MDS (PAPER I AND II) 
One key information for devising new therapies is which cells to target. Whether cancer cells 
are stochastically or hierarchically organized is fundamental to therapeutic targeting. Previous 
studies had suggested that the dysplastic cells originate from transformed normal 
hematopoietic stem cells (Nilsson et al., 2000). The concept of human cancer stem cells rests 
on the existence of rare self-renewing stem cells capable of spawning descendents which are 
functionally and molecularly distinct and unable to form new tumors. If the hierarchical 
relationship between stem cells and progenitors is conserved in MDS, one could potentially 
use acquired somatic mutations as genetic tools by interrogating which candidate stem and 
progenitor populations harbour the somatic mutations found in bulk MDS bone marrow.  
We used flow cytometric cell sorting to prospectively isolate stem and progenitor cells from 
low and intermediate-1 risk MDS patients, both with (paper II) and without (paper I and II) 
deletion of 5q. We observed phenotypically distinct stem and progenitor cell compartments 
similar to the normal hematopoietic hierarchical organization found in healthy bone marrow. 
Given that the flow cytometric profiles resembled those of normal controls, it was important 
to determine whether these stem and progenitor populations were clonally involved MDS 
cells or residual normal cells. Using flourescence in situ hybridisation we found that the 
prospectively isolated stem and progenitor cells were clonally involved. In order to rule out 
that aberrant expression of cell surface markers had compromised the fidelity with which 
these populations could be identified prospectively, we sought to characterize these 
populations functionally and molecularly (paper I). Colony-forming assays in methylcellulose 
confirmed that GMPs and MEPs exclusively gave rise to myeloid and erythroid colonies, 
respectively. Using long-term culture CFU-assays and xenotransplantation in NSG-mice we 
assessed whether the hierarchical organization is conserved in MDS. Only the lin-
CD34+CD38-CD90+CD45RA- stem cells could give rise to CFUs after long-term culture 
and were able to engraft immunocompromised mice.  We found no evidence of engraftment 
of any downstream progenitor population in the investigated patients, suggesting that self-
renewal is confined to MDS stem cells. Consistent with the functional evaluation of the 
different subsets, the gene expression signatures of stem cells, GMPs and MEPs were similar 
to their respective counterpart in healthy bone marrow.  
We also investigated the impact of lenalidomide therapy in del(5q) patients. Longitudinal 
samples from del(5q) patients treated with lenalidomide demonstrated that that the 
distribution of HSC and multipotent progenitors remained similar to healthy controls, 
irrespective of whether the sample was taken at diagnosis or during lenalidomide treatment 
(paper II). Notably, we observed that the frequency of GMP at diagnosis was significantly 
suppressed in del(5q) MDS with a concomitant increase in CMP (paper I and paper II). This 
finding in MDS patients with the deletion 5q is in line with findings reported from other 
studies of low-risk MDS (Pang et al., 2013; Will et al., 2012) and thus appears to be not 
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confined to del(5q) MDS. Importantly, upon treatment with lenalidomide, the frequencies 
reverted to their normal distribution (paper II). In a small number of patients (n=5) who 
progressed to leukemia, we had access to longitudinal samples. This allowed us study the 
kinetic changes in stem and progenitor cell subsets within the same patient over time, both 
during treatment and progression of the disease. The only common finding was that one 
predominant subset expanded prior to progression, the type of subset, however, varied from 
patient to patient (paper II). Assessment of del(5q) clonal size in sorted stem and progenitor 
cells as well as bulk bone marrow demonstrated persistence of del(5q) during lenalidomide 
treatment and despite the fact that several of the patients exhibited a complete clinical 
response to lenalidomide. The only patient who initially showed complete clearance of 
del(5q) from the mononuclear cell compartment of bulk bone marrow, i.e., the compartment 
that is analyzed in clinical routine, had minimal involvement in all myeloid progenitors. In 
contrast, more than half of the lin-CD34+CD38-CD90+CD45RA- stem cell compartment 
remained part of the del(5q) clone. These findings are in line with a previous report 
suggesting a selective resistance of del(5q) HSC to lenalidomide treatment (Tehranchi et al., 
2010).  
 
8.2 MINING THE MUTATIONAL LANDSCAPE OF MDS FOR MARKERS OF 
CANCER STEM CELLS AND DISEASE PROGRESSION (PAPER I AND II) 
One inherent shortcoming of previous studies of cancer stem cell function is the assessment 
outside of the cells' natural habitat. Prior to this study, the existence of human cancer stem 
cells has not been demonstrated in the patients themselves. The concept had however been 
demonstrated in murine models by fate-mapping using genetic lineage-tracing (Chen et al., 
2012; Schepers et al., 2012).  
We sought to exploit the fact that the vast majority of MDS cases harbour somatic mutations 
and used these mutations in a fate-mapping approach. We employed both targeted sequencing 
of 84 genes previously implicated in myeloid malignancies as well as exome sequencing of 
unfractionated bone marrow. We then performed targeted sequencing of individually picked 
colonies derived from long-term clones of single cells and flow-sorted MDS stem and 
progenitor populations. Our finding of all detected mutations being acquired in the MDS stem 
cells demonstrated that only these cells self-renew in the patients provided that only self 
renewing cells can give rise to stable mutations. If mutations were only detectable in 
downstream progenitors, this would indicate that these cells had re-acquired the ability to 
self-renew - a feature that is normally lost during lineage commitment. Overall, the 
mutational landscape in del(5q) MDS patients appeared to be relatively stable, while 
additional mutations were identified in two other patients who later progressed to AML. 
Importantly, the acquisition of new mutations pre-dated clinical signs of progression. We 
were able to elucidate the chronological order in which these mutations were acquired by 
performing targeted sequencing of whole-genome-amplified single-cell colonies derived from 
long-term cultures of single MDS stem cells. Both patients had acquired recurrent mutations 
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in TP53 prior to clinical signs of disease progression, e.g., an increase in blasts. One patient 
was found to have an additional putative passenger-mutation in PIFO at a high frequency 
which was confined to MEP-progenitors and absent from the stem cell compartment. 
Strikingly, the MEP-compartment was significantly expanded, suggesting that these MEPs 
had reacquired the ability to self-renew. This observation is in line with current models of 
leukemic evolution in AML where increased clonal off-branching is observed (Ding et al., 
2012b; Walter et al., 2012; Welch et al., 2012).  
An additional curious finding from this study was that somatic mutations were acquired in 
cells that already had the del(5q) abnormality present. A notable exception to this were 
patients with ringsideroblasts; in these patients, SF3B1 mutations preceded the acquisition of 
del(5q). Taken together, the experiments in paper I provide definitive evidence that rare 
human cancer stem cells exist in vivo. This finding has broad biological implications for our 
understanding of cancer biology and clinical implications by specifically targeting the MDS 
stem cell population. 
The molecular mechanisms why certain del(5q) MDS patients progress have not been 
elucidated. Therefore, we are currently unable to predict which patients are likely to progress. 
Jädersten et al. previously found that the presence of small TP53-mutated subclones predict 
adverse outcome and demonstrated that these subclones expand with progression of disease 
(Jädersten et al., 2011). In addition, the advent of next-generation sequencing methodologies 
has demonstrated that the majority of MDS patients harbour recurrent somatic mutations in a 
number of myeloid candidate genes (Bejar et al., 2011; Haferlach et al., 2014; Papaemmanuil 
et al., 2013; Yoshida et al., 2011). As several of these genes are associated with clinical 
outcome, we hypothesized that the acquisition of certain somatic mutations might help 
explain disease progression in del(5q) MDS. We used our cohort of longitudinal patient 
samples to study whether certain mutations are associated with disease progression. The vast 
majority of patients (84%) were found to harbour at least one recurrent mutation. The 
presence of mutations did not correlate with other clinical parameters, e.g., blood counts, age, 
other cytogenetic aberrations. Of note, the mutational landscape in a pure del(5q) cohort 
differed from low-risk MDS in general; splicing gene mutations occured less frequently and 
overall the mutational spectrum resembled that of higher-risk MDS patients. While 22 
patients in our cohort were treated with lenalidomide, 13 were not. We did not detect any 
difference between these two groups in terms of number or type of mutations. At diagnosis, 
about one-third had no mutation and the presence of one or more mutation did not predict 
progression. However, absence of mutations was suggestive of freedom from progression. 
Thirteen patients progressed to high-risk MDS or leukemia at a median of 85 months after 
diagnosis. Conspicuously, progression was associated with the detection of a finite subset of 
new mutations, namely TP53, TET2, and RUNX1. Two single cases harboured mutations in 
SF3B1 and PTPN11 but due to the low number no significant conclusion could be drawn 
from this. Of 9 patients who progressed to AML, 7 had mutations in TP53, which were 
present in the earliest sample in one case and acquired in the remaining six cases.  Of note, 
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five of the six patients had been analyzed previously by deep sequencing and found to have 
no mutation at diagnosis, further arguing that these mutations had been acquired along the 
way. Immunohistochemical detection of p53 was strongly correlated with detection of 
mutation of TP53 by targeted sequencing, confirming our earlier findings (Saft et al., 2014). 
We detected mutations in RUNX1 and TET2 in the remaining two patients with leukemic 
progression; these mutations were present at both time-points at which these patients were 
sampled. Patients who progressed to higher-risk MDS were all found to carry mutations in 
TET2. Remarkably, testing positive for any of three mutations (TP53, TET2, RUNX1) 
conveyed a high probability of progression (13/16, 81%), regardless of whether or not the 
mutations were present at diagnosis or acquired subsequently. An important finding was that 
the new mutations were detected well before signs of clinical progression occured; the 
median time was 42 months from mutation detection to clinical evidence of progressive 
disease. 
Our finding that the frequency of mutation is higher in later samples than at diagnosis is in 
line with a model where initial mutations occur in HSC leading to clonal hematopoiesis 
which might develop into MDS. Acquisition of additional mutations then leads to disease 
progression. The fact that several patients showed increased allele burdens and acquisition of 
new mutation during treatment and natural course of the disease suggest that clonal evolution 
is frequent event in patients with lower-risk del(5q) MDS. Of 13 patients with progressive 
disease, 12 were treated with lenalidomide. TP53 was the major culprit and identified in 7 of 
9 patients who developed leukemia. Since normal function of p53 is required for apoptosis of 
erythroid cells due to haploinsufficiency of RPS14, this might help to explain the apparent 
propensity for del(5q) cells developing TP53 mutations. In theory, treatment with 
lenalidomide might select for TP53 mutations. In that regard it is interesting to note that some 
patients exhibited more than one TP53 mutation. Furthermore, our study highlights the 
marked clonal heterogeneity and instability, likely explaining disease progression of lower-
risk del(5q) MDS treated with lenalidomide. Curiously, compared to other MDS subtypes, 
isolated del(5q) in lower-risk MDS has generally been associated with low risk for leukemic 
transformation, while presence of del(5q) is associated with an adverse prognosis in either de 
novo AML or in MDS with complex karyotypes (Milosevic et al., 2012; Sebaa et al., 2012; 
Zemanova et al., 2014). TP53 mutations migh help explain this observation. 
While we observed TP53 mutations in the majority of patients which progressed to leukemia 
or higher-risk disease, additional mutations were associated with progression or loss of 
treatment response. Mutations in RUNX1 were univariably associated with disease 
progression and observed in 3 of 13 patients. Due to allele burden we were able to exclude 
the possibility of RUNX1 germline mutations. RUNX1 has a well-documented association 
with poor prognosis in MDS as well as AML (Chen et al., 2007; Steensma et al., 2005; Tang 
et al., 2009). We observed mutations in TET2 in 6 of 13 patients who showed signs of disease 
progression. Three patients were found to harbour mutations in both TET2 as well as TP53; 
however, our data cannot provide evidence that this occured by independent mutational 
processes. TET2 mutations are quite common in myeloid neoplasms in general. Their impact 
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in MDS is a contentious issue (Abdel-Wahab et al., 2009; Smith et al., 2010), while one study 
found TET2 mutations to be associated with shorter survival in MDS patients undergoing 
hematopoietic cell transplantation (Bejar et al., 2014). 
 
8.3 THE ROLE OF THE MICROENVIROMENT IN MDS WITH DELETION OF 5Q 
(PAPER II AND III) 
The microenvironment provides input to all cells in the bone marrow, thereby regulating their 
maintenance, proliferation and differentiation. In the setting of hematological disease, 
changes in the bone marrow microenvironment can be the consequence of chronic 
pertubation of bone marrow homeostasis or the neoplastic clone actively instigating a 
remodelling towards a cancer-supportive microenvironment (Li and Neaves, 2006; 
Raaijmakers, 2011; Schepers et al., 2013; Vener et al., 2008; Walkley et al., 2007). While it is 
generally believed that the inability to produce mature progeny has mainly intrinsic reasons, 
i.e., due to defects in the hematopoietic stem and progenitor cells themselves, we sought to 
determine to what extent the microenvironment might contribute. To this end, we cultured 
mesenchymal stromal cells from untreated del(5q) patients as well as healthy volunteers. 
Comparing their gene expression profiles, we confirmed the absence of expression of 
hematopoietic genes, suggesting that our cultures were not contaminated by remaining 
hematopoietic cells, i.e., macrophages, a finding that can lead to erroneous conclusions and 
has led to significant debate in the past (Ramakrishnan et al., 2006; Simmons et al., 1987). 
Fluorescence in situ hybridisation analysis on del(5q) stromal cells failed to detect the clonal 
del(5q) abnormality above background, suggesting negligible contamination by 
macrophages. Our studies of MSC from a pure cohort of low to intermediate-1 risk patients 
with deletion of 5q are in line with previous findings that the marrow stroma is not derived 
from the malignant clone in MDS (Ramakrishnan et al., 2006). 
MSC cultures from untreated del(5q) MDS patients as well as healthy volunteers expressed 
gene signatures typical for MSC, albeit no genes were expressed in a statistically significant 
manner (paper II), not even when specifically examining genes that had previously been 
implicated in the interaction of niche cells with hematopoietic stem cells (Méndez-Ferrer et 
al., 2010). While seemingly at odds with recent reports of stromal abnormalities in multiple 
subtypes of MDS (Geyh et al., 2013; Medyouf et al., 2014), our studies confirm earlier 
studies by other groups who found the stromal abnormalities to be reversible and MDS 
stroma capable of supporting normal hematopoiesis in vitro (Deeg et al., 2000; Soenen-Cornu 
et al., 2005). 
As in vitro cultures are by nature artificial approximations and hence might fail to detect 
abnormalities, we examined bone marrow biopsies in del(5q) MDS patients before and 
during lenalidomide treatment and compared them to healthy controls. We observed a 
significantly higher microvessel density (MVD) in del(5q) MDS compared to normal 
controls. Lenalidomide treatment, at least during the initial phase, decreased microvessel 
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density in all patients analyzed. Upon therapeutic failure, microvessel density increased in 4 
of 5 patients and was paralleled by a concomitant increase in bone marrow cellularity. We 
also observed that lenalidomide decreased the number of CD68+ macrophages which 
mirrored a decrease in cellularity. However, we failed to detect an increase in macrophages in 
del(5q) patients prior to treatment compared to controls. Based mainly on murine but also 
some human studies, several surrogate markers for mesenchymal stem cells have been put 
forward, e.g. nestin, CD271, CD146. Analysis of staining patterns for these markers 
demonstrated labeling confined to rare perivascular mesenchymal cells, e.g., endothelial and 
advential sinusoidal cells. The staining pattern we observed is consistent to what has been 
reported from murine and human studies. Importantly, we were unable to detect quantitative 
differences in expression patterns for any of these markers between del(5q) MDS and normal 
bone marrow. While these findings do not formally rule out any microenvironmental 
irregularities, they demonstrate that - based on the MSC markers tested - lenalidomide does 
not exert its main therapeutic effect by reshaping the cellular composition of the 
microenvironment. Our data in patients with del(5q) MDS neither suggests that the 
microenvironment constrains healthy hematopoiesis. However, the issue whether the 
microenviroment is perturbed or merely a bystander has been a heavily contentious issue in 
the literature, not only for MDS but for myeloid diseases in general (Deeg, 2002; Ferrer et al., 
2013; Medyouf et al., 2014; Raaijmakers, 2011; Raaijmakers and Scadden, 2008; Schepers et 
al., 2015). Some of the conflicting findings are probably explained by the heterogeneity of the 
diseases studied, particularly in MDS. In order to draw relevant conclusions, we propose to 
study carefully selected subgroups of patients with closely matched clinical characteristics, 
similar to what we have done in low to intermediate-1 del(5q) MDS. 
Lenalidomide produces complete cytogenetic remission, eradicating most mature and 
progenitor del(5q) cells. However, the rare disease-sustaining MDS stem cells fail to be 
eradicated during lenalidomide therapy. These resistant cancer stem cells are the probable 
reason for why the majority of patients relapse (Fenaux et al., 2011; Giagounidis et al., 2012; 
Saft et al., 2014; Tehranchi et al., 2010). We hypothesized this resistance to be the cause for 
continued accrual of somatic mutations in the stem cell compartment. Whether the resistance 
is confined to stem cells only or extends to other populations is unknown.  
Abnormal megakaryocytes with hypolobated nuclei are one of the hallmarks of del(5q) MDS. 
As megakaryocytes have recently been implicated as important niche cells in the regulation 
of HSC (Bruns et al., 2014; Zhao et al., 2014), we hypothesized that these cells might have 
potential implications for HSC responding to lenalidomide treatment. Therefore, we sought to 
study megakaryocytes as a component of the non-mesenchymal niche in MDS and to 
determine the response of abnormal megakaryocytes with hypolobated nuclei to lenalidomide 
therapy. 
Examining the bone marrows of 22 del(5q) patients we observed the persistence of the 
pathognomonic megakaryocytes with hypolobated nuclei in all patients, despite lenalidomide 
leading to complete clinical responses. As clinical response might not correlate with complete 
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cytogenetic remission, we investigated a subset of 21 patients from the MDS-004 study. Four 
patients had available biopsies at time of complete cytogenetic remission. The del(5q) 
abnormality was completely absent in 3 patients at 12 weeks post-randomization, and at 48 
weeks in the remaining patient. In all 4 cases, megakaryocytes with hypolobated nuclei 
persisted. We were able to validate these findings in our own cohort of 22 consecutive 
lenalidomide-treated del(5q) MDS patients seen at Karolinska University Hospital. In all 
patients that had biopsy material available at time of CCyR, we were able to clearly identify 
megakaryocytes with hypolobated nuclei. Furthermore, we provide evidence that the 
pathognomonic nuclear hypolobation is directly associated with the clonal del(5q) aberration. 
Irrespective of nuclear content, megakaryocytes of 2N, 4N, 8N or 16N harboured del(5q), 
suggesting that the feature of hypolobation is not correlated to nuclear content. This is in line 
with findings from murine models of del(5q) MDS (Barlow et al., 2010). 
Given that megakaryocytes are rare and readily identifiable on routine morphology, we 
propose that focussing on megakaryocytes is a viable strategy for evaluating patients for 
long-term remission and where discontinuation of lenalidomide is considered. Remarkably, 
one of our patients who exhibited complete hematological remission 2 years after 
discontinuation of lenalidomide, demonstrated clonal involvement in 2 of 23 
megakaryocytes. 
Our findings suggest that the entire megakaryocyte lineage from HSC to MEP to 
megakaryocytes might be resistant to treatment with lenalidomide. Whether or not this 
resistance might help explain the high relapse-rate of lenalidomide-treated patients remains 
an open question. Of note, HSC primed for differentiation towards the megakaryocytic 
lineage have been shown to reside at the apex of the HSC hierarchy (Sanjuan-Pla et al., 2013) 
and there is evidence for fast-track differentiation from HSC via MEP to megakaryocytes 
(Haas et al., 2015; Yamamoto et al., 2013). We believe this to underlie the high-degree of 
lenalidomide resistance in the megakaryocytic lineage as a whole and entertain the notion that 
HSC and megakaryocytes can favour each other's existence in a symbiotic manner. 
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9 CONCLUDING REMARKS & FUTURE DIRECTIONS 
We have demonstrated that a fate-mapping approach based on tracing somatic mutations 
back to prospectively isolated cell populations is a viable strategy for identifying cancer-
initiating cells. Similar approaches should prove informative in a wide variety of 
malignancies. In the case of del(5q) MDS, we have shown that the disease-driving cell is the 
normal hematopoietic stem cell where somatic mutations are accrued. An obvious 
explanation for this is that HSC are the only cells where the transcriptional machinery is 
rigged for self-renewal; all downstream progenitors would need to reactivate the self-renewal 
machinery first - otherwise, mutations in these populations remain transitory events. Of note, 
specifically in the case for MDS with deletion of 5q, we observed the acquisition of somatic 
mutations after the deletion of 5q had occurred, arguing that progression of the disease results 
from the accumulation of additional mutations in the stem cell compartment. 
Our findings in paper II extended these observations and demonstrated that patients with 
lower-risk del(5q) have a high tendency towards clonal evolution and that this is clearly 
linked to progression, particularly in patients treated with lenalidomide. This is in contrast to 
lenalidomide-treated MDS patients without deletion of 5q, where the rate of clonal evolution 
is much lower (Chesnais et al., 2016). 
Our longitudinal data clearly indicate that progression results from an increase in the 
mutational burden over time and is thus unlikely to be predicted by mutational profiling 
solely at diagnosis. While mutations in TP53 detected at diagnosis have been shown to 
predict disease progression even in low-risk MDS (Jädersten et al., 2009; 2011), our 
longitudinal follow-up of these patients in paper II demonstrated the emergence of TP53 
mutations shortly before time of progression, arguing that these are acquired rather than 
present at undetectable levels at diagnosis. Intriguingly, the patients who progressed in our 
study showed a strong bias towards having been treated with lenalidomide. While this might 
be the result of a higher treatment incentive in patients with a less benign disease course, it is 
possible that lenalidomide exerts selective pressure on resistant driver subclones within the 
HSC compartment. Lenalidomide exerts its main therapeutic effects via decreasing the need 
for transfusion (List et al., 2006) and by a HSC-specific mechanism involving targeted 
destruction of CK1a via the ubiquitylation pathway (Krönke et al., 2015). Given that both the 
successful reversal of anemia and abrogation of the clonal advantage of del(5q) depend on 
intact TP53 (Barlow et al., 2010; Schneider et al., 2014), it seems likely that lenalidomide's 
therapeutic effect is dependent upon unmutated, wild-type TP53. The recent findings by Lode 
et al. confirm our observations, as these investigators reported that a statistically significant 
higher exposure to lenalidomide was observed in patients with progressive disease and 
specifically in patients with TP53 clonal evolution (Lodé et al., 2017).  
Several centers are already using targeted sequencing panels to aid in the diagnosis of MDS - 
this will likely become part of the standard work-up of patients with suspected MDS over the 
next few years, both for aiding in and confirming the diagnosis and for determining 
prognosis. Similar to what has recently been published for AML (Papaemmanuil et al., 2016), 
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a large international effort is underway by the International Working Group for MDS 
Molecular Prognosis (MDS IWG-PM) in order to assess the value of mutation testing in risk 
stratification. Preliminary results (ASH abstract 2015) on approximately 2000 patients 
suggest that a mutation in any of the following genes, TP53, RUNX1, NRAS, EZH2, conferred 
high-risk for progression. This prognostic information was independent from the IPSS-R 
score. These findings suggest that mutational profiling can contribute critical information that 
allows the forecasting of the natural history of MDS in a particular patient. However, as 
shown in this body of work, patients are continually acquiring mutations during their disease 
course. We therefore suggest that assessment of mutational status be performed at regular 
follow-up visits, particularly in patients with TP53 mutations. 
Our flow cytometric analysis in papers I and II demonstrated that unless the patient showed 
clinical signs of progression, neither lenalidomide treatment nor the presence of mutations led 
to profound changes in the relative organization of stem and progenitor cell populations. 
Although the absolute size of these subsets are impossible to quantitate due to the inherent 
technical variability of the bone marrow draw (Pang et al., 2011), the lack of apparent relative 
expansions suggests that available niche space might constrain expansion to a certain extent. 
Thus, it seems likely, that certain particular driver mutations must be acquired leading to 
transformative events, e.g., remodeling of the microenvironment, to allow for expansion of 
transformed clones (Schepers et al., 2013; 2015). Our finding of the whole megakaryocytic 
branch of hematopoiesis being lenalidomide-resistant is important in this context (paper III). 
If human megakaryocytes regulate HSC pool size similarly to what has been reported in 
mouse models (Bruns et al., 2014; Zhao et al., 2014), it is conceivable that del(5q) 
megakaryocytes might favour del(5q) stem cells over normal ones. This hypothesis is easily 
testible in mouse models by specifically deleting the syntenic regions equivalent to human 
del(5q) (Barlow et al., 2010) in murine megakaryocytes. Perhaps, specifically targeting 
del(5q) megakaryocytes might offer a viable therapeutic modality for patients. 
 
Figure 4. Model of the hematopoietic niche (mesenchymal and non-mesenchymal/hematopoietic) 
regulating and restricting the expansion of stem cells. Modified after (Lobo et al., 2007). 
 
Normal stem cells depend on the niche which restricts their expansion
stem cell 

in its niche mature cellstransiently amplifying progenitor cells
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